var title_f19_46_20192="CT scan thickened pericardium";
var content_f19_46_20192=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Computed tomography (CT) showing thickened pericardium in a patient with pericardial mesothelioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 342px; height: 291px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This axial image of a contrast-enhanced thoracic CT scan reveals a thickened pericardiuim (arrow). This young man was referred for pericardiectomy to treat what was initially diagnosed as tuberculous constrictive pericarditis. At the time of surgery, the pathologic diagnosis was mesothelioma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ralph Shabetai, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_46_20192=[""].join("\n");
var outline_f19_46_20192=null;
var title_f19_46_20193="Pachyonychia congenita - nails";
var content_f19_46_20193=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pachyonychia congenita",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Thickened discolored nails are present in this patient with pachyonychia congenita.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_46_20193=[""].join("\n");
var outline_f19_46_20193=null;
var title_f19_46_20194="Silver nitrate: Pediatric drug information";
var content_f19_46_20194=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Silver nitrate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?41/53/42834?source=see_link\">",
"    see \"Silver nitrate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?42/28/43459?source=see_link\">",
"    see \"Silver nitrate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Ophthalmic Agent, Miscellaneous",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Topical Skin Product",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/53/42834?source=see_link\">",
"      see \"Silver nitrate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Sticks: Apply to mucous membranes and other moist skin surfaces only on area to be treated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical solution: Apply a cotton applicator dipped in solution on the affected area 2-3 times/week for 2-3 weeks",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F221055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Applicator sticks, topical: Silver nitrate 75% and potassium nitrate 25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical: 0.5% (960 mL); 10% (30 mL); 25% (30 mL); 50% (30 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F221041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1049898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store applicator sticks in a dry place since moisture causes the oxidized film to dissolve; protect from light",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Astringent; cauterization of wounds; germicidal; removal of granulation tissue, corns, and warts",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F221085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Burning and skin irritation, staining of the skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Methemoglobinemia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to silver nitrate or any component; not for use on broken skin or cuts",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1049895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not use applicator sticks on the eyes. Prolonged use may result in skin discoloration. Silver nitrate is a caustic agent and inappropriate use may cause chemical burns. Skin contact time with applicator sticks should be extremely short when used in neonates or on thin delicate skin contact.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Free silver ions precipitate bacterial proteins by combining with chloride in tissue forming silver chloride; coagulates cellular protein to form an eschar",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1049907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Not readily absorbed from mucous membranes",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1049900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/28/43459?source=see_link\">",
"      see \"Silver nitrate: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Discontinue topical preparation if redness or irritation develop; silver nitrate solution may stain skin",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cushing AH and Smith S, &ldquo;Methemoglobinemia With Silver Nitrate Therapy of a Burn: Report of a Case,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1969, 74(4):613-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/46/20194/abstract-text/4886190/pubmed\" id=\"4886190\" target=\"_blank\">",
"        4886190",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12788 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-708A4DD6E0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_46_20194=[""].join("\n");
var outline_f19_46_20194=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049903\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049896\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221055\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221041\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049898\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049905\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221085\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049908\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049895\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300040\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222926\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049894\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049907\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049900\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12788\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12788|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/53/42834?source=related_link\">",
"      Silver nitrate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/28/43459?source=related_link\">",
"      Silver nitrate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_46_20195="Extensive hidradenitis suppurativa with multiple sinus tracts";
var content_f19_46_20195=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F57893&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F57893&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Extensive hidradenitis suppurativa with multiple sinus tracts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 397px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This picture shows the initial surgical unroofing of the inflamed hidradenitis suppurativa inflamed nodule, the lateral extension of the sinus tract, and an additional inferior lateral sinus tract. Gentle probing with blunt scissors has identified another sinus tract that requires unroofing with beveled skin edges.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: F William Danby, MD, FRCPC, FAAD. Copyright &copy; 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_46_20195=[""].join("\n");
var outline_f19_46_20195=null;
var title_f19_46_20196="Ropinirole: Patient drug information";
var content_f19_46_20196=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ropinirole: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18615?source=see_link\">",
"     see \"Ropinirole: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F219144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Requip&reg;;",
"     </li>",
"     <li>",
"      Requip&reg; XL&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F219145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      CO Ropinirole;",
"     </li>",
"     <li>",
"      JAMP-Ropinirole;",
"     </li>",
"     <li>",
"      PMS-Ropinirole;",
"     </li>",
"     <li>",
"      RAN&trade;-Ropinirole;",
"     </li>",
"     <li>",
"      Requip&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692011",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Parkinson's disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692040",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat restless leg syndrome.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702890",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ropinirole or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698652",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Falling asleep during activities such as eating or talking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11034 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-9CEA1CDAAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_46_20196=[""].join("\n");
var outline_f19_46_20196=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219144\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219145\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013100\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013099\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013104\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013105\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013107\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013102\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013103\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013108\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013109\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18615?source=related_link\">",
"      Ropinirole: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_46_20197="Tipranavir: Patient drug information";
var content_f19_46_20197=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tipranavir: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"     see \"Tipranavir: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F786677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aptivus&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2935530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aptivus&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700462",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rare reports of bleeding into the brain have happened. Harm to the liver has also been reported. Patients with liver disease might have more chance of having this problem. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat HIV infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703041",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tipranavir or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are",
"       <b>",
"        not",
"       </b>",
"       taking ritonavir.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703831",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have very bad liver disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697204",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor. This drug may raise blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have hemophilia, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697729",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy in HIV disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696918",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use a hormone-related kind of birth control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696711",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not breast-feed if you have HIV disease unless your doctor tells you to.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High cholesterol level.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698150",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High triglyceride level.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697937",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in body fat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad bleeding may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow capsule whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699345",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Throw away any part not used after 2 months.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11449 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-DA858D2583-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_46_20197=[""].join("\n");
var outline_f19_46_20197=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F786677\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2935530\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028407\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028409\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028408\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028413\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028414\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028416\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028411\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028412\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028417\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028418\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=related_link\">",
"      Tipranavir: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_46_20198="Post-lumbar puncture headache";
var content_f19_46_20198=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Post-lumbar puncture headache",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/46/20198/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/46/20198/contributors\">",
"     Christina Sun-Edelstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/46/20198/contributors\">",
"     Christine L Lay, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/46/20198/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/46/20198/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/46/20198/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/46/20198/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/46/20198/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headache, which occurs in 10 to 30 percent of patients following lumbar puncture, is one of the most common complications of the procedure. Post-lumbar puncture headache (PLPHA; also known as post-dural puncture headache) is caused by leakage of cerebrospinal fluid from the dura with resultant traction on pain-sensitive structures.",
"   </p>",
"   <p>",
"    This topic will review PLPHA. Other aspects of lumbar puncture are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19561?source=see_link\">",
"     \"Lumbar puncture: Technique; indications; contraindications; and complications in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1891 Quincke introduced the lumbar puncture (LP) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/1\">",
"     1",
"    </a>",
"    ], and in 1898 Bier suffered and was the first to report PLPHA [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/2\">",
"     2",
"    </a>",
"    ]. He proposed that ongoing leakage of cerebrospinal fluid (CSF) through the dural puncture site was the cause of the headache. This belief is maintained today; it is supposed that CSF leakage through the dural rent made by the LP needle exceeds the rate of CSF production, resulting in low CSF volume and pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/3\">",
"     3",
"    </a>",
"    ]. The reported incidence of PLPHA ranges from 10 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of note, cerebral venous thrombosis must also be considered as a possible cause of persisting headache following LP, since LP can rarely precipitate a cerebral venous thrombosis. However, unlike PLPHA, the headache related to cerebral venous thrombosis does not typically change with posture, and the severity usually increases in the acute phase of illness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=see_link\">",
"     \"Etiology, clinical features, and diagnosis of cerebral venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PLPHA characteristically present with frontal or occipital headache within 6 to 72 hours of the procedure that is exacerbated in an upright position and improved in the supine position [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. Associated symptoms may include nausea, vomiting, dizziness, tinnitus, neck stiffness, and visual changes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/5\">",
"     5",
"    </a>",
"    ]. Without treatment, the headache typically lasts 2 to 15 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In various studies of patients undergoing LP for diagnosis or for spinal anesthesia, common risk factors for PLPHA have included female gender, a prior history of headache, age 20 to 40 (or 30 to 50) years compared with other ages, and bevel orientation perpendicular to the longitudinal fibers of the dura [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/4,6,7\">",
"     4,6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two other factors had been thought to increase the risk of developing PLPHA: a larger amount of fluid removed and the experience of the physician performing the procedure. However, neither appears to be important, as physician experience was not a risk factor in the series of 501 patients with PLPHA [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/6\">",
"     6",
"    </a>",
"    ], and the volume of fluid removed was not a risk factor in a meta-analysis from the AAN report [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have attempted to identify factors that decrease the risk of PLPHA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Needle size and orientation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Higher needle gauge (smaller needle bore) and orientation of the needle bevel parallel to the longitudinal fibers of the dura have clearly been shown to decrease the incidence of PLPHA [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. As an example, one study found that the rate of PLPHA was much lower with 24 to 27-gauge needles compared with 20 to 22 gauge needles (5 to 12 versus 20 to 40 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, technical difficulty may be more likely with smaller bore needles, since these needles tend to bend during insertion and require a longer period for the confirmatory CSF to appear at the hub after successful placement [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/8\">",
"     8",
"    </a>",
"    ]. Because of the higher failure rate with smaller bore needles, a 22-gauge needle is typically used for routine lumbar puncture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Atraumatic versus cutting needles",
"    </span>",
"    &nbsp;&mdash;&nbsp;An atraumatic spinal needle causes a smaller dural defect than a conventional cutting spinal needle and should theoretically result in a lower incidence of PLPHA [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on the available data, derived mainly from one high quality study [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/12\">",
"     12",
"    </a>",
"    ], the AAN concluded that use of an atraumatic spinal needle for diagnostic LP in adult patients reduces the frequency of PLPHA [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/11\">",
"     11",
"    </a>",
"    ]. This observation is supported by a well-designed, prospective, double-blind trial involving 230 patients who were randomly assigned to diagnostic LP with a 22-gauge atraumatic Sprotte needle or a conventional 22-gauge cutting Quincke needle [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/12\">",
"     12",
"    </a>",
"    ]. Use of the atraumatic needle compared with the cutting needle was associated with a significantly lower frequency of PLPHA (12.2 versus 24.4 percent, respectively). The frequency of PLPHA in both groups was higher than reported in most prior series, and this higher frequency was attributed to the relatively younger age (mean 40 years) of the study population.",
"   </p>",
"   <p>",
"    In a later trial that randomly assigned 58 patients to LP with a 22-gauge atraumatic Whitacre needle or a conventional 22-gauge Quincke needle, the frequency of PLPHA was significantly lower with the atraumatic needle compared with the conventional needle (3 versus 36 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One analysis found that atraumatic needles are cost-effective compared with cutting needles when the costs of lumbar puncture and treatment of PLPHA are considered [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/14\">",
"     14",
"    </a>",
"    ]. Although data are limited, atraumatic needles may require greater technical expertise for optimal use and may be prone to a higher failure rate (ie, more unsuccessful LP attempts) compared with cutting needles [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/11,15\">",
"     11,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Patient positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different methods of patient positioning after the LP have been proposed to reduce the incidence of PLPHA. However, removal of the needle with the patient in the prone position and placement of the patient in either the supine or prone position after the procedure have not been shown to change the incidence of PLPHA [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/2,16\">",
"     2,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Bedrest",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite recommendations for bed rest following LP, this remedy has",
"    <strong>",
"     not",
"    </strong>",
"    been shown to significantly decrease the risk of PLPHA [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. A meta-analysis of 16 randomized controlled trials of LP performed for anesthesia, myelography, or diagnostic purposes found no evidence in any trial that longer bed rest was superior to immediate patient mobilization or shorter bed rest [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/19\">",
"     19",
"    </a>",
"    ]. The relative risk of headache among patients undergoing a diagnostic LP was 0.97 with longer bed rest. A similar lack of benefit was noted in a second meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since PLPHA is typically mild and resolves spontaneously, conservative therapy for the first 24 hours is generally recommended. Such conservative therapy includes bed rest and oral analgesics, including opioids. Hydration and abdominal binders are not necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with moderate to severe prolonged headache refractory to conservative measures, epidural blood patch and intravenous caffeine are probably effective [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Epidural blood patch",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review published in 2010 concluded that epidural blood patch is effective compared with both conservative treatment and sham procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/22\">",
"     22",
"    </a>",
"    ], based upon the results of three randomized controlled trials with a total of 86 subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. The first epidural blood patch gives relief in the majority of cases, and the second one is successful in nearly all cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/26\">",
"     26",
"    </a>",
"    ]. Thus, epidural blood patch is considered the treatment of choice for patients with PLPHA who fail an initial trial of conservative management [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/22,26\">",
"     22,26",
"    </a>",
"    ]. In addition, epidural blood patch is considered the definitive therapy of moderate to severe headache following epidural anesthesia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/40/39562?source=see_link&amp;anchor=H13#H13\">",
"     \"Adverse effects of neuraxial analgesia and anesthesia for obstetrics\", section on 'Postdural puncture headache'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Placement of an epidural blood patch is a relatively simple procedure in which autologous blood is injected epidurally at or near the site of the prior LP. Epidural blood patching works via two mechanisms. The early, almost immediate, effect is related to volume replacement resulting from dural tamponade, and the latent effect results from sealing of the cerebrospinal fluid leak. Adverse effects are uncommon but include back pain, leg paresthesias, and fever. Some patients require more than one epidural blood patch before headache relief is achieved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Caffeine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy and tolerability of intravenous caffeine as treatment for PLPHA was documented in a randomized controlled trial of 41 patients with refractory PLPHA headache following spinal anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/21,27,28\">",
"     21,27,28",
"    </a>",
"    ]. More patients assigned to intravenous caffeine",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/6/32866?source=see_link\">",
"     sodium benzoate",
"    </a>",
"    (500 mg) than normal saline reported relief of headache within two hours of the infusion (75 versus 15 percent). Its mechanism of action is thought to be vasoconstriction of the cerebral vasculature.",
"   </p>",
"   <p>",
"    For intravenous infusion, caffeine is combined with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/6/32866?source=see_link\">",
"     sodium benzoate",
"    </a>",
"    , which is added to increase the solubility of caffeine. This combination is available in two formulations: caffeine 125",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    and sodium benzoate 125",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    (2 mL); and caffeine 121",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    and sodium benzoate 129",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    (2 mL). For PLPHA, one suggested regimen is to give caffeine 500 mg diluted in 1000 mL of normal saline as a slow intravenous infusion over one hour [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/29\">",
"     29",
"    </a>",
"    ], followed by 1000 mL of normal saline alone infused over one hour. A second dose of caffeine can be given in four hours if headache pain is unrelieved.",
"   </p>",
"   <p>",
"    Oral caffeine (300 mg) was evaluated in a placebo-controlled trial of 40 postpartum women with PLPHA [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/30\">",
"     30",
"    </a>",
"    ]. At four hours, the improvement in pain score was marginally better for the caffeine than the placebo group [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/21\">",
"     21",
"    </a>",
"    ]. However, headache recurrence was noted the following day for six patients (30 percent) who had relief at four hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H690174963\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other agents that have been evaluated for the treatment of PLPHA in small controlled trials or case series include epidural saline [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/31\">",
"     31",
"    </a>",
"    ], intramuscular adrenocorticotropic hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/32-35\">",
"     32-35",
"    </a>",
"    ], oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/36\">",
"     36",
"    </a>",
"    ], intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/37\">",
"     37",
"    </a>",
"    ], oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/38\">",
"     38",
"    </a>",
"    ], and subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"     sumatriptan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/39\">",
"     39",
"    </a>",
"    ]. Of these, the limited available data suggest modest effectiveness only for gabapentin, hydrocortisone, and theophylline [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epidural saline is thought to transiently compress the subarachnoid space and allow the dural defect to seal. Because saline disperses from the epidural space quickly, this technique is associated with a high rate of recurrence. In one series, all patients treated with epidural saline reported relief of their headache, but the headache later recurred in 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several small studies described the use of adrenocorticotropic hormone for the treatment of PLPHA, with success rates of 70 to 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. In contrast, a randomized trial in 18 patients found no difference in the severity of headache or requirement for an epidural blood patch with adrenocorticotropic hormone compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20198/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the available therapies for treatment of PLPHA and the fact that this condition is usually self-limited, conservative measures are recommended for the first 24 hours, including bed rest and oral analgesics that do not affect platelet function. If such conservative therapy is not effective, we suggest epidural blood patch as the next step.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/23/44402?source=see_link\">",
"       \"Patient information: Lumbar puncture (spinal tap) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Post-lumbar puncture headache (PLPHA) is caused by leakage of CSF from the dura and traction on pain-sensitive structures (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Headache occurs in 10 to 30 percent of patients following lumbar puncture. Patients with PLPHA characteristically present with frontal or occipital headache within 12 to 24 hours of the procedure. The headache is exacerbated in an upright position and improved in the supine position (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Risk factors for PLPHA include female gender, a prior history of headache, age of approximately 20 to 50 years, and bevel orientation perpendicular to the longitudinal fibers of the dura (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk factors'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Higher needle gauge (smaller needle bore) and orientation of the needle bevel parallel to the longitudinal fibers of the dura have clearly been shown to decrease the incidence of PLPHA. Use of an atraumatic spinal needle in adults also reduces the frequency of PLPHA (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Prevention'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Bed rest immediately following lumbar puncture has",
"      <strong>",
"       not",
"      </strong>",
"      been shown to significantly decrease the risk of PLPHA (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Prevention'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Because most PLPHAs are mild and resolve spontaneously, conservative therapy for the first 24 hours is generally recommended. Such conservative therapy includes bed rest and oral analgesics, including opioids (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      For patients with moderate to severe PLPHA that is prolonged (&gt;24 hours) and refractory to conservative measures, we suggest treatment with epidural blood patch (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Epidural blood patch'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/1\">",
"      Silberstein SD, Marcelis J. Headache associated with changes in intracranial pressure. Headache 1992; 32:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/2\">",
"      Raskin NH. Lumbar puncture headache: a review. Headache 1990; 30:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/3\">",
"      Fern&aacute;ndez E. Headaches associated with low spinal fluid pressure. Headache 1990; 30:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/4\">",
"      Amorim JA, Gomes de Barros MV, Valen&ccedil;a MM. Post-dural (post-lumbar) puncture headache: risk factors and clinical features. Cephalalgia 2012; 32:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/5\">",
"      Morgenlander JC. Lumbar puncture and CSF examination. Answers to three commonly asked questions. Postgrad Med 1994; 95:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/6\">",
"      Kuntz KM, Kokmen E, Stevens JC, et al. Post-lumbar puncture headaches: experience in 501 consecutive procedures. Neurology 1992; 42:1884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/7\">",
"      Evans RW, Armon C, Frohman EM, Goodin DS. Assessment: prevention of post-lumbar puncture headaches: report of the therapeutics and technology assessment subcommittee of the american academy of neurology. Neurology 2000; 55:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/8\">",
"      Morewood GH. A rational approach to the cause, prevention and treatment of postdural puncture headache. CMAJ 1993; 149:1087.",
"     </a>",
"    </li>",
"    <li>",
"     Dieterich, M, Perkin, GD. Post-lumbar puncture headache syndrome. In: Neurologic Disorders: Course and Treatment, Brand, T, Caplan, LR, Dichland, J, et al, (Eds), Academic Press, San Diego 1996, p.59.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/10\">",
"      Vallejo MC, Mandell GL, Sabo DP, Ramanathan S. Postdural puncture headache: a randomized comparison of five spinal needles in obstetric patients. Anesth Analg 2000; 91:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/11\">",
"      Armon C, Evans RW, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Addendum to assessment: Prevention of post-lumbar puncture headaches: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2005; 65:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/12\">",
"      Strupp M, Schueler O, Straube A, et al. \"Atraumatic\" Sprotte needle reduces the incidence of post-lumbar puncture headaches. Neurology 2001; 57:2310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/13\">",
"      Lavi R, Yarnitsky D, Yernitzky D, et al. Standard vs atraumatic Whitacre needle for diagnostic lumbar puncture: a randomized trial. Neurology 2006; 67:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/14\">",
"      Tung CE, So YT, Lansberg MG. Cost comparison between the atraumatic and cutting lumbar puncture needles. Neurology 2012; 78:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/15\">",
"      Thomas SR, Jamieson DR, Muir KW. Randomised controlled trial of atraumatic versus standard needles for diagnostic lumbar puncture. BMJ 2000; 321:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/16\">",
"      Bolder PM. Postlumbar puncture headache in pediatric oncology patients. Anesthesiology 1986; 65:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/17\">",
"      Carbaat PA, van Crevel H. Lumbar puncture headache: controlled study on the preventive effect of 24 hours' bed rest. Lancet 1981; 2:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/18\">",
"      Vilming ST, Schrader H, Monstad I. Post-lumbar-puncture headache: the significance of body posture. A controlled study of 300 patients. Cephalalgia 1988; 8:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/19\">",
"      Thoennissen J, Herkner H, Lang W, et al. Does bed rest after cervical or lumbar puncture prevent headache? A systematic review and meta-analysis. CMAJ 2001; 165:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/20\">",
"      Sudlow C, Warlow C. Posture and fluids for preventing post-dural puncture headache. Cochrane Database Syst Rev 2002; :CD001790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/21\">",
"      Basurto Ona X, Mart&iacute;nez Garc&iacute;a L, Sol&agrave; I, Bonfill Cosp X. Drug therapy for treating post-dural puncture headache. Cochrane Database Syst Rev 2011; :CD007887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/22\">",
"      Boonmak P, Boonmak S. Epidural blood patching for preventing and treating post-dural puncture headache. Cochrane Database Syst Rev 2010; :CD001791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/23\">",
"      van Kooten F, Oedit R, Bakker SL, Dippel DW. Epidural blood patch in post dural puncture headache: a randomised, observer-blind, controlled clinical trial. J Neurol Neurosurg Psychiatry 2008; 79:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/24\">",
"      Seebacher J, Ribeiro V, LeGuillou JL, et al. Epidural blood patch in the treatment of post dural puncture headache: a double blind study. Headache 1989; 29:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/25\">",
"      Sandesc D, Lupei MI, Sirbu C, et al. Conventional treatment or epidural blood patch for the treatment of different etiologies of post dural puncture headache. Acta Anaesthesiol Belg 2005; 56:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/26\">",
"      Mokri B. Low cerebrospinal fluid pressure syndromes. Neurol Clin 2004; 22:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/27\">",
"      Sechzer PH, Abel L. Post-spinal anesthesia headache treated with caffeine. Evaluation with demand method. Part 1. Curr Ther Res Clin Exp 1978; 24:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/28\">",
"      Sechzer PH. Post-spinal anesthesia headache treated with caffeine. Part II: Intracranial vascular distention, a key factor. Curr Ther Res Clin Exp 1979; 26:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/29\">",
"      Y&uuml;cel A, Ozyal&ccedil;in S, Talu GK, et al. Intravenous administration of caffeine sodium benzoate for postdural puncture headache. Reg Anesth Pain Med 1999; 24:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/30\">",
"      Camann WR, Murray RS, Mushlin PS, Lambert DH. Effects of oral caffeine on postdural puncture headache. A double-blind, placebo-controlled trial. Anesth Analg 1990; 70:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/31\">",
"      RICE GG, DABBS CH. The use of peridural and subarachnoid injections of saline solution in the treatment of severe postspinal headache. Anesthesiology 1950; 11:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/32\">",
"      Foster P. ACTH treatment for post-lumbar puncture headache. Br J Anaesth 1994; 73:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/33\">",
"      Gupta S, Agrawal A. Postdural puncture headache and ACTH. J Clin Anesth 1997; 9:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/34\">",
"      C&aacute;novas L, Barros C, G&oacute;mez A, et al. Use of intravenous tetracosactin in the treatment of postdural puncture headache: our experience in forty cases. Anesth Analg 2002; 94:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/35\">",
"      Rucklidge MW, Yentis SM, Paech MJ. Synacthen Depot for the treatment of postdural puncture headache. Anaesthesia 2004; 59:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/36\">",
"      Erol DD. The effect of oral gabapentin on postdural puncture headache. Acute Pain 2006; 8:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/37\">",
"      Noyan Ashraf MA, Sadeghi A, Azarbakht Z, et al. Evaluation of intravenous hydrocortisone in reducing headache after spinal anesthesia: a double blind controlled clinical study [corrected]. Middle East J Anesthesiol 2007; 19:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/38\">",
"      Feuerstein TJ, Zeides A. Theophylline relieves headache following lumbar puncture. Placebo-controlled, double-blind pilot study. Klin Wochenschr 1986; 64:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20198/abstract/39\">",
"      Connelly NR, Parker RK, Rahimi A, Gibson CS. Sumatriptan in patients with postdural puncture headache. Headache 2000; 40:316.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3353 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-9CEA1CDAAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_46_20198=[""].join("\n");
var outline_f19_46_20198=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Needle size and orientation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Atraumatic versus cutting needles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Patient positioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Bedrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Epidural blood patch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Caffeine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H690174963\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/40/39562?source=related_link\">",
"      Adverse effects of neuraxial analgesia and anesthesia for obstetrics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7594?source=related_link\">",
"      Etiology, clinical features, and diagnosis of cerebral venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19561?source=related_link\">",
"      Lumbar puncture: Technique; indications; contraindications; and complications in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/23/44402?source=related_link\">",
"      Patient information: Lumbar puncture (spinal tap) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_46_20199="Sacroiliitis grade 3 example 1";
var content_f19_46_20199=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F68009%7ERHEUM%2F79174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F68009%7ERHEUM%2F79174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Sacroiliitis grade 3 example 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral sacroiliitis grade 3 with widening and sclerosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Xenofon Baraliakos, Rheumazentrum Ruhrgebiet, Herne, Germany.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Sacroiliitis grade 3 example 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral sacroiliitis grade 3.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Sheng Guang Li, PLA Hospital, China.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_46_20199=[""].join("\n");
var outline_f19_46_20199=null;
var title_f19_46_20200="Parapsoriasis (small plaque and large plaque parapsoriasis)";
var content_f19_46_20200=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Parapsoriasis (small plaque and large plaque parapsoriasis)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/46/20200/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/46/20200/contributors\">",
"     Laura Y McGirt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/46/20200/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/46/20200/contributors\">",
"     John A Zic, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/46/20200/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/46/20200/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/46/20200/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H11633013\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parapsoriasis is a group of uncommon dermatoses occurring mainly in adults and characterized by erythematous and scaly patches of variable size, chronic course, and resistance to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20200/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Parapsoriasis is considered to be a cutaneous lymphoproliferative disorder. There are two main types: small plaque parapsoriasis (SPP) and large plaque parapsoriasis (LPP). SPP is usually a chronic benign condition; in contrast, LPP is regarded as a premalignant dermatosis with a substantial risk of progression to mycosis fungoides, a type of cutaneous T cell lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides\", section on 'Premycotic period'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SPP and LPP will be discussed in this topic. Other cutaneous lymphoproliferative disorders and mycosis fungoides are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/61/17369?source=see_link\">",
"       \"Pityriasis lichenoides et varioliformis acuta (PLEVA)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7546?source=see_link\">",
"       \"Lymphomatoid papulosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88963253\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small plaque parapsoriasis (SPP) and large plaque parapsoriasis (LPP) are rare disorders. Their incidence and prevalence are not known. Both SPP and LPP occur most commonly in middle-aged or older individuals; approximately two-thirds of patients are male [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20200/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11633020\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology and pathogenesis of small plaque parapsoriasis (SPP) and large plaque parapsoriasis (LPP) are unknown. Both are thought to be cutaneous T cell lymphoproliferative disorders. The superficial dermal infiltrate is composed primarily of CD4",
"    <sup>",
"     +",
"    </sup>",
"    T cells. Dominant T cell clonality has been demonstrated in many cases of LPP and in a few cases of SPP [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20200/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. However, the presence of a dominant T cell clone does not necessarily increase the malignant potential of these dermatoses [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20200/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hypothesis of a viral etiology for parapsoriasis has not been confirmed. Evidence of infection with lymphotropic viruses (eg, Epstein-Barr virus, cytomegalovirus, and human herpesviruses (HHV) 6 and HHV8) has not been found consistently in patients with parapsoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20200/abstract/10-15\">",
"     10-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56547675\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histologic features of small plaque parapsoriasis (SPP) are nonspecific and resemble those of a mild eczema. The epidermis manifests mild spongiosis (intercellular edema) with focal areas of parakeratosis, scale, and exocytosis of small lymphocytes with normal mature morphology. In chronic lesions, the spongiosis is often absent and the epidermis develops a psoriasiform acanthosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20200/abstract/16\">",
"     16",
"    </a>",
"    ]. The dermis shows edema, a sparse perivascular lymphocytic infiltrate, and dilation of the papillary vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20200/abstract/16-18\">",
"     16-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunostaining reveals a nonspecific infiltrate composed mainly of CD4",
"    <sup>",
"     +",
"    </sup>",
"    T lymphocytes. In some cases, polymerase chain reaction studies demonstrate a dominant clonal pattern of T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20200/abstract/5,7\">",
"     5,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The histology of large plaque parapsoriasis (LPP) reveals [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20200/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Psoriasiform epidermal hyperplasia (or atrophy in poikilodermatous areas [ie, areas with a combination of mottled pigmentation, telangiectasia, and epidermal atrophy])",
"     </li>",
"     <li>",
"      Vacuolization in the basal keratinocyte layer",
"     </li>",
"     <li>",
"      Capillary dilation",
"     </li>",
"     <li>",
"      Brisk lymphocytic infiltrate with a band-like distribution that can obscure the dermo-epidermal junction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The infiltrate is composed of small lymphocytes, some of which may have cerebriform, convoluted nuclei. There is focal lymphocytic epidermotropism, but Pautrier microabscesses (ie, clusters of atypical lymphocytes in the epidermis), a classic histologic characteristic of mycosis fungoides, are usually absent in LPP [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20200/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunophenotyping demonstrates normal",
"    <span class=\"nowrap\">",
"     CD4/CD8",
"    </span>",
"    ratio and maintenance of the pan-T cell antigen CD7, a marker of mature T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20200/abstract/19\">",
"     19",
"    </a>",
"    ]. However, some studies have demonstrated that benign T cell infiltrates, including parapsoriasis, may lose CD7 expression [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20200/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Both SPP and LPP have increased expression of the",
"    <span class=\"nowrap\">",
"     dendritic/Langerhans",
"    </span>",
"    cell marker CD1a [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20200/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clonal T cell receptor (TCR) gene rearrangements have been identified by PCR analysis in up to 50 percent of LPP cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20200/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. However, the presence of a predominant T cell clone is not diagnostic of LPP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11633027\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small plaque parapsoriasis (SPP) typically presents with asymptomatic, pink or yellowish-brown macules or patches 2 to 5 cm in diameter (",
"    <a class=\"graphic graphic_picture graphicRef87291 graphicRef87292 \" href=\"UTD.htm?21/38/22122\">",
"     picture 1A-B",
"    </a>",
"    ). Macules and patches are often round or oval and variably scaly. The trunk, flanks, and proximal extremities are most commonly involved [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20200/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A distinctive variant of SPP called &ldquo;digitate dermatosis&rdquo; presents with elongated (digitate, finger-shaped) patches with an atrophic, cigarette-paper-like surface. Lesions are typically located on the flanks, along the skin cleavage lines (",
"    <a class=\"graphic graphic_picture graphicRef87290 \" href=\"UTD.htm?33/14/34022\">",
"     picture 1C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In contrast to SPP, large plaque parapsoriasis (LPP) presents with large, irregularly shaped erythematous, dusky red or brown patches with fine scaling (",
"    <a class=\"graphic graphic_picture graphicRef87288 graphicRef87289 graphicRef68028 graphicRef86681 \" href=\"UTD.htm?32/61/33754\">",
"     picture 2A-D",
"    </a>",
"    ). Lesions frequently show epidermal atrophy (&ldquo;cigarette paper&rdquo; wrinkling) or poikiloderma (ie, the combination of mottled pigmentation, telangiectasia, and epidermal atrophy). LPP typically involves areas not exposed to the sun (eg, buttocks, thighs, lower trunk, flexural surfaces, and, in women, breasts and inframammary areas).",
"   </p>",
"   <p>",
"    Clinical variants with overlapping features of SPP and LPP may be seen in some patients. Parapsoriasis lesions are most often asymptomatic or mildly pruritic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57288599\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both small plaque parapsoriasis (SPP) and large plaque parapsoriasis (LPP) may persist for years or decades. Patients may report a history of waxing and waning. Lesions may disappear after sun exposure in the summer (eg, at the beach) and recur during the winter months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56547880\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parapsoriasis is suspected in patients presenting with persistent, asymptomatic, erythematous and scaly patches of variable size mainly located on the trunk. A skin biopsy for histopathologic examination is necessary to establish the diagnosis. A 4 mm punch biopsy is usually sufficient; however, multiple biopsies may be required if lesions of diverse morphology (eg, erythematous, atrophic, poikilodermatous) are present. Repeated biopsies over time also may be needed in difficult cases with overlapping clinical and histologic features of SPP and LPP. Skin biopsy techniques are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=see_link\">",
"     \"Skin biopsy techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The definitive diagnosis of small plaque parapsoriasis (SPP) or large plaque parapsoriasis (LPP) is based upon the combination of clinical and histologic findings (see",
"    <a class=\"local\" href=\"#H11633027\">",
"     'Clinical manifestations'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H56547675\">",
"     'Histopathology'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Small plaque parapsoriasis",
"      </strong>",
"      &ndash; Characteristic clinical findings include asymptomatic, erythematous round or oval macules &lt;5 cm in diameter mainly located on the trunk (",
"      <a class=\"graphic graphic_picture graphicRef87291 \" href=\"UTD.htm?25/55/26488\">",
"       picture 1A",
"      </a>",
"      ) or elongated, &rdquo;digitate&rdquo; lesions on the flanks, parallel to the skin cleavage lines (",
"      <a class=\"graphic graphic_picture graphicRef87292 \" href=\"UTD.htm?17/20/17732\">",
"       picture 1B",
"      </a>",
"      ). Histologic features include those of a superficial dermatitis (eg, mild spongiosis [intercellular edema] with focal parakeratosis, and sparse perivascular lymphocytic infiltrate). Although these findings are nonspecific, they support the diagnosis of SPP when combined with clinical features and course. &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Large plaque parapsoriasis",
"      </strong>",
"      &ndash; Characteristic clinical findings include erythematous patches larger than 5 cm, irregularly shaped, atrophic or poikilodermatous, located on the lower trunk, buttocks, and thighs (",
"      <a class=\"graphic graphic_picture graphicRef87288 graphicRef87289 graphicRef68028 graphicRef86681 \" href=\"UTD.htm?32/61/33754\">",
"       picture 2A-D",
"      </a>",
"      ). Histologic features include epidermal hyperplasia or atrophy, a band-like infiltrate composed of small lymphocytes, some of which may have cerebriform, convoluted nuclei, and focal single-cell epidermotropism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11633041\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H799317\">",
"    <span class=\"h2\">",
"     Large plaque versus small plaque parapsoriasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;LPP is in most cases distinguished from SPP by the larger size, asymmetric distribution, and irregular shape of its lesions, which are less discrete and often poikilodermatous. The distinctive variant of SPP that presents with digitate lesions parallel to skin lines on the flanks is easily differentiated from LPP on clinical grounds. However, clinical overlap may occur between SPP and LPP in patients presenting with large and small or intermediate size patches. In cases in which the diagnosis is unclear, histologic features or repeat biopsies may be helpful. (See",
"    <a class=\"local\" href=\"#H56547675\">",
"     'Histopathology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10848393\">",
"    <span class=\"h2\">",
"     Small plaque parapsoriasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of SPP includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Pityriasis lichenoides chronica",
"      </strong>",
"      &ndash; Pityriasis lichenoides chronica typically presents with recurrent crops of erythematous scaly papules that spontaneously regress over several weeks to months (",
"      <a class=\"graphic graphic_picture graphicRef71210 \" href=\"UTD.htm?18/50/19233\">",
"       picture 3",
"      </a>",
"      ). Histology shows a band-like lymphohistiocytic infiltrate. There is exocytosis, extravasation of erythrocytes, and focal parakeratosis.",
"     </li>",
"     <li>",
"      <strong>",
"       Guttate psoriasis",
"      </strong>",
"      &ndash; Guttate psoriasis presents with small, erythematous plaques with fine scale (",
"      <a class=\"graphic graphic_picture graphicRef64836 graphicRef55141 \" href=\"UTD.htm?34/35/35384\">",
"       picture 4A-B",
"      </a>",
"      ). Histology of early lesions demonstrates mild acanthosis, papillary dermal edema, capillary dilatation, and a sparse lymphocytic infiltrate. Older lesions show hyperkeratosis, parakeratosis, acanthosis, and collections of neutrophils in the epidermis (Munro microabscesses). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/29/32216?source=see_link\">",
"       \"Guttate psoriasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pityriasis rosea",
"      </strong>",
"      &ndash; The presence of a herald patch and resolution within a few weeks to months differentiates pityriasis rosea from SPP (",
"      <a class=\"graphic graphic_picture graphicRef87126 graphicRef69881 \" href=\"UTD.htm?19/32/19977\">",
"       picture 5A-B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/35/18999?source=see_link\">",
"       \"Pityriasis rosea\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Nummular dermatitis",
"      </strong>",
"      &ndash; Nummular dermatitis is characterized by intensely pruritic, coin-shaped lesions of eczematous dermatitis, with crusting and serous oozing on close inspection (",
"      <a class=\"graphic graphic_picture graphicRef58067 graphicRef66792 \" href=\"UTD.htm?33/55/34679\">",
"       picture 6A-B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=see_link&amp;anchor=H25#H25\">",
"       \"Overview of dermatitis\", section on 'Nummular dermatitis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21277278\">",
"    <span class=\"h2\">",
"     Large plaque parapsoriasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of LPP includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mycosis fungoides (MF)",
"      </strong>",
"      &ndash; The clinical differentiation of early (patch stage) MF and LPP may be difficult or impossible in some cases. Clinical monitoring and repeated skin biopsies often are required for definitive diagnosis. The primary patches of LPP are more likely to fade in the summer than the more persistent patches of early MF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Histologically, MF is characterized by a papillary dermal infiltrate of small to medium-sized atypical mononuclear cells with cerebriform nuclei, single-cell epidermotropism of atypical lymphocytes, or atypical lymphocytes forming intraepidermal aggregates (Pautrier microabscesses) (",
"    <a class=\"graphic graphic_picture graphicRef83483 \" href=\"UTD.htm?43/35/44600\">",
"     picture 7",
"    </a>",
"    ). Spongiosis (intercellular edema in the epidermis) is",
"    <strong>",
"     not",
"    </strong>",
"    a feature of MF.",
"   </p>",
"   <p>",
"    However, some of these findings may be missing in early MF. Although there are no universally accepted minimal criteria for the diagnosis of MF, the International Society for Cutaneous Lymphoma and the European Organization of Research and Treatment of Cancer (EORTC) has devised an algorithm for the diagnosis of early MF based upon the integration of clinical, histopathologic, molecular, and immunophenotypic criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20200/abstract/9\">",
"     9",
"    </a>",
"    ]. Cases that fail to meet any specific set of criteria for the diagnosis of early MF may be diagnosed as LPP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides\", section on 'Diagnostic algorithm'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Contact dermatitis",
"      </strong>",
"      &ndash; Subacute or chronic allergic contact dermatitis (ACD) may be difficult to differentiate from LPP (",
"      <a class=\"graphic graphic_picture graphicRef87440 \" href=\"UTD.htm?24/2/24615\">",
"       picture 8",
"      </a>",
"      ). On histology, both diseases show minimal or absent spongiosis and lymphocytic exocytosis. However, history of allergen exposure, positive patch test results to suspected allergens, and response to treatment and avoidance measures support the diagnosis of ACD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11943?source=see_link\">",
"       \"Clinical features and diagnosis of allergic contact dermatitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Plaque psoriasis",
"      </strong>",
"      &ndash; In contrast with the flat lesions of LPP, the psoriasis plaques are erythematous with sharply defined margins raised above the surrounding normal skin (",
"      <a class=\"graphic graphic_picture graphicRef87442 graphicRef87441 graphicRef87443 \" href=\"UTD.htm?42/34/43562\">",
"       picture 9A-C",
"      </a>",
"      ). There is frequent involvement of elbows and knees and nail pitting may be seen at close inspection (",
"      <a class=\"graphic graphic_picture graphicRef70962 \" href=\"UTD.htm?15/7/15474\">",
"       picture 10",
"      </a>",
"      ). Histology confirms the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27625?source=see_link&amp;anchor=H10#H10\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of psoriasis\", section on 'Plaque psoriasis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11633048\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10848471\">",
"    <span class=\"h2\">",
"     Small plaque parapsoriasis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H799408\">",
"    <span class=\"h3\">",
"     Indications for treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SPP usually are asymptomatic and require minimal or no treatment. Scaling and mild pruritus may be controlled with emollients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20200/abstract/24\">",
"     24",
"    </a>",
"    ]. However, treatment is required for patients whose pruritus is not controlled with emollients or who have cosmetic concerns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3365268\">",
"    <span class=\"h3\">",
"     Initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with SPP who require treatment, we suggest topical corticosteroids rather than simple emollients. We generally use moderate to high potency corticosteroids (group two to four (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    )) once or twice a day for 8 to 12 weeks. Emollients can be used liberally in conjunction with topical corticosteroids. The clearance of all skin lesions indicates a good response to treatment. Recurrence is common and may occur weeks to months after stopping the treatment. Recurrent lesions can be treated with another course of topical corticosteroids.",
"   </p>",
"   <p>",
"    The use of topical corticosteroids for the treatment of SPP has not been evaluated in randomized trials. Their use is based upon clinical experience and indirect evidence of efficacy in inducing lesion regression from observational studies of early mycosis fungoides [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20200/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17017?source=see_link&amp;anchor=H19277711#H19277711\">",
"     \"Treatment of early stage (IA to IIA) mycosis fungoides\", section on 'Topical corticosteroids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The long-term use of topical corticosteroids, particularly those belonging to the high- and super high-potency groups, may result in skin atrophy, telangiectasia, and striae. In addition, if applied to large skin surfaces, topical corticosteroids may result in systemic absorption and adrenal suppression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=see_link&amp;anchor=H16#H16\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3365384\">",
"    <span class=\"h3\">",
"     Poor response to initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with unsatisfactory response to topical corticosteroids (eg, clearance of less than 50 percent of lesions), we suggest phototherapy with broad-band or narrow-band UVB or PUVA. Phototherapy is generally administered two to three times per week for several months, until clearance of lesions is achieved. The frequency of treatments is gradually tapered to once per week or less and then discontinued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26775?source=see_link\">",
"     \"UVB therapy (broadband and narrowband)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is limited evidence of efficacy of phototherapy in the treatment of SPP from small case series or single case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20200/abstract/27-31\">",
"     27-31",
"    </a>",
"    ]. The optimal length of treatment and the tapering schedule have not been determined. In one study including 14 patients with SPP, treatment duration of less than four months was associated with relapse in all patients after an average time of six months [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20200/abstract/30\">",
"     30",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3365143\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the chronic, benign course of SPP, patients with SPP can be monitored with yearly total body skin examination. Changing or progressing lesions should be biopsied because there are scattered reports of patients with an initial diagnosis of SPP who subsequently developed overt mycosis fungoides [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20200/abstract/3,5\">",
"     3,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10848478\">",
"    <span class=\"h2\">",
"     Large plaque parapsoriasis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109157996\">",
"    <span class=\"h3\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with LPP require treatment to control pruritus if present and suppress the skin lesions. They also require close clinical monitoring because they have a substantial risk of developing mycosis fungoides. The approach to treatment depends upon the extent and severity of disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest topical corticosteroids as initial treatment for patients with LPP who typically have limited areas of involvement and only mild skin atrophy. (See",
"      <a class=\"local\" href=\"#H57289237\">",
"       'Topical corticosteroids'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      We suggest phototherapy with broad or narrow band UVB or PUVA rather than topical corticosteroids in the following situations (see",
"      <a class=\"local\" href=\"#H57289244\">",
"       'Phototherapy'",
"      </a>",
"      below):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with LPP who have extensive skin involvement, marked skin atrophy, or poikiloderma",
"     </li>",
"     <li>",
"      Patients who fail to respond to topical corticosteroids (ie, clearance of less than 50 percent of lesions)",
"     </li>",
"     <li>",
"      Patients who have disease progression",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients for whom a clearcut distinction between LPP and early mycosis fungoides cannot be made either clinically or histologically may be treated with skin directed therapies as indicated for stage IA mycosis fungoides. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17017?source=see_link&amp;anchor=H3#H3\">",
"       \"Treatment of early stage (IA to IIA) mycosis fungoides\", section on 'Stage IA disease'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57289237\">",
"    <span class=\"h3\">",
"     Topical corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the initial treatment of patients with LPP, we use high- to super high-potency topical corticosteroids (groups one and two (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    )) twice daily for 12 weeks and continue once daily or taper off if improvement is noted. Emollients can be used liberally in conjunction with topical corticosteroids.",
"   </p>",
"   <p>",
"    The clearance of all or most skin lesions indicates a good response to treatment. If no response is observed after 12 weeks of treatment, topical corticosteroids should be stopped. Patients who do not respond to topical corticosteroids may be treated with phototherapy. (See",
"    <a class=\"local\" href=\"#H57289244\">",
"     'Phototherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In patients who respond to topical corticosteroids, recurrence is common and may occur weeks to months after stopping the treatment. Recurrent lesions can be treated with another course of topical corticosteroids.",
"   </p>",
"   <p>",
"    The use of topical corticosteroids for the treatment of LPP has not been evaluated in randomized trials. Indirect evidence of efficacy in inducing lesion regression is derived from observational studies of patients with patch stage mycosis fungoides [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20200/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17017?source=see_link&amp;anchor=H19277711#H19277711\">",
"     \"Treatment of early stage (IA to IIA) mycosis fungoides\", section on 'Topical corticosteroids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The long-term use of topical corticosteroids, particularly those belonging to the high- and super high-potency groups, may result in skin atrophy, telangiectasia, and striae. In addition, if applied to large skin surfaces, topical corticosteroids may result in systemic absorption and adrenal suppression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=see_link&amp;anchor=H16#H16\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57289244\">",
"    <span class=\"h3\">",
"     Phototherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phototherapy with broad or narrow band UVB or PUVA may be indicated for patients with LPP who have extensive skin involvement, skin atrophy or poikiloderma, lack of response to initial treatment with topical corticosteroids, or disease progression despite treatment with topical corticosteroids. &nbsp;",
"   </p>",
"   <p>",
"    Phototherapy is generally administered two to three times per week for several months, until clearance of lesions is achieved. The frequency of treatments is gradually tapered to once per week or less and then discontinued. The benefits of a long-term maintenance treatment have not been evaluated. Recurrences may be treated by resuming the initial phototherapy schedule. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26775?source=see_link\">",
"     \"UVB therapy (broadband and narrowband)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33160?source=see_link\">",
"     \"Psoralen plus ultraviolet A (PUVA) photochemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no randomized trials or large observational studies of phototherapy for the treatment of LPP. Its use is based upon evidence of efficacy in inducing lesion regression from small case series and indirect evidence of efficacy in early mycosis fungoides [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20200/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17017?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of early stage (IA to IIA) mycosis fungoides\", section on 'Phototherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The short-term and long-term adverse effects of phototherapy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26775?source=see_link&amp;anchor=H10844620#H10844620\">",
"     \"UVB therapy (broadband and narrowband)\", section on 'Short- and long-term adverse effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33160?source=see_link&amp;anchor=H31513947#H31513947\">",
"     \"Psoralen plus ultraviolet A (PUVA) photochemotherapy\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57289251\">",
"    <span class=\"h3\">",
"     Topical chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of topical nitrogen mustard (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/57/40853?source=see_link\">",
"     mechlorethamine",
"    </a>",
"    ) or topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    has been described in patients with LPP, particularly those in whom LPP cannot clearly be distinguished from MF [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20200/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. We generally avoid topical nitrogen mustard and carmustine because of the associated toxicities. These agents and their adverse effects are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17017?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of early stage (IA to IIA) mycosis fungoides\", section on 'Topical nitrogen mustard (HN2)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17017?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of early stage (IA to IIA) mycosis fungoides\", section on 'Topical carmustine (BCNU)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3365150\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with LPP require a close clinical monitoring because of the substantial risk of evolution to mycosis fungoides [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20200/abstract/3,37\">",
"     3,37",
"    </a>",
"    ]. A total body skin examination ideally should be performed every six months. Patients should be counseled about the risk of developing MF and advised to seek medical attention if thicker plaques or nodules develop. There are no guidelines suggesting how often patients with LPP should be rebiopsied to detect a possible progression to MF. However, significant clinical change (eg, thicker plaques, increased atrophy, nodules, ulceration, an &ldquo;ugly duckling&rdquo; lesion) is an indication for biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11633055\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both small plaque parapsoriasis (SPP) and large plaque parapsoriasis (LPP) may persist for years or decades. Most experts consider SPP to be a benign disorder without malignant potential. However, there are rare reports of patients with an initial diagnosis of SPP who subsequently developed MF [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20200/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. In retrospective observational studies, approximately 10 to 30 percent of cases of LPP evolved to overt MF [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20200/abstract/2,3,37\">",
"     2,3,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11633062\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parapsoriasis, including small plaque parapsoriasis (SPP) and large plaque parapsoriasis (LPP) is a group of uncommon dermatoses occurring in adults and characterized by erythematous and scaly patches of variable size, chronic course, and poor response to treatment. (See",
"      <a class=\"local\" href=\"#H11633013\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H88963253\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SPP presents with round or oval erythematous patches &lt;5 cm or elongated &ldquo;digitate&rdquo; lesions on the trunk and proximal extremities (",
"      <a class=\"graphic graphic_picture graphicRef87291 graphicRef87292 graphicRef87290 \" href=\"UTD.htm?39/55/40826\">",
"       picture 1A-C",
"      </a>",
"      ). The clinical diagnosis is supported by the histologic finding of a nonspecific dermatitis with spongiosis and a sparse perivascular lymphocytic infiltrate. (See",
"      <a class=\"local\" href=\"#H11633027\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H56547880\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      LPP presents with lesions &gt;5 cm, irregularly shaped, frequently atrophic or poikilodermatous, and typically localized in areas not exposed to the sun (eg, lower trunk, buttocks, and thighs) (",
"      <a class=\"graphic graphic_picture graphicRef87288 graphicRef87289 graphicRef68028 graphicRef86681 \" href=\"UTD.htm?32/61/33754\">",
"       picture 2A-D",
"      </a>",
"      ). The diagnosis is based upon the clinical presentation and the histologic finding of a dense dermal infiltrate of small lymphocytes, some of which have cerebriform nuclei, and focal single-cell epidermotropism. (See",
"      <a class=\"local\" href=\"#H56547880\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H56547675\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with SPP, treatment is not necessary. However, for patients who are symptomatic with pruritus or have cosmetic concerns, we suggest topical corticosteroids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We generally use moderate to high potency corticosteroids (groups two to four (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"       table 1",
"      </a>",
"      )) once or twice a day for 8 to 12 weeks. We suggest phototherapy with broad or narrow band UVB or PUVA if topical corticosteroids are ineffective (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10848471\">",
"       'Small plaque parapsoriasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with LPP require treatment to control pruritus and suppress the skin lesions. They also require close clinical monitoring since they have a substantial risk of developing mycosis fungoides. (See",
"      <a class=\"local\" href=\"#H10848478\">",
"       'Large plaque parapsoriasis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3365150\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with LPP who have limited areas of involvement and mild skin atrophy, we suggest topical corticosteroids as initial treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We use high- to super high-potency topical corticosteroids (groups one and two (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"       table 1",
"      </a>",
"      )) twice daily for 12 weeks. (See",
"      <a class=\"local\" href=\"#H57289237\">",
"       'Topical corticosteroids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with LPP who have extensive skin involvement or skin atrophy or poikiloderma, we suggest phototherapy with broadband or narrowband UVB or PUVA rather than topical corticosteroids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Phototherapy is also appropriate when there is a lack of response to initial treatment with topical corticosteroids or disease progression despite treatment with topical corticosteroids. Phototherapy is generally administered three to five times per week for several months, until clearance of lesions is achieved. (See",
"      <a class=\"local\" href=\"#H57289244\">",
"       'Phototherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/1\">",
"      Benmam&aacute;n O, S&aacute;nchez JL. Comparative clinicopathological study on pityriasis lichenoides chronica and small plaque parapsoriasis. Am J Dermatopathol 1988; 10:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/2\">",
"      Lambert WC, Everett MA. The nosology of parapsoriasis. J Am Acad Dermatol 1981; 5:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/3\">",
"      V&auml;kev&auml; L, Sarna S, Vaalasti A, et al. A retrospective study of the probability of the evolution of parapsoriasis en plaques into mycosis fungoides. Acta Derm Venereol 2005; 85:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/4\">",
"      Simon M, Flaig MJ, Kind P, et al. Large plaque parapsoriasis: clinical and genotypic correlations. J Cutan Pathol 2000; 27:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/5\">",
"      Belousova IE, Vanecek T, Samtsov AV, et al. A patient with clinicopathologic features of small plaque parapsoriasis presenting later with plaque-stage mycosis fungoides: report of a case and comparative retrospective study of 27 cases of \"nonprogressive\" small plaque parapsoriasis. J Am Acad Dermatol 2008; 59:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/6\">",
"      Kikuchi A, Naka W, Harada T, et al. Parapsoriasis en plaques: its potential for progression to malignant lymphoma. J Am Acad Dermatol 1993; 29:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/7\">",
"      Haeffner AC, Smoller BR, Zepter K, Wood GS. Differentiation and clonality of lesional lymphocytes in small plaque parapsoriasis. Arch Dermatol 1995; 131:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/8\">",
"      Klemke CD, Dippel E, Dembinski A, et al. Clonal T cell receptor gamma-chain gene rearrangement by PCR-based GeneScan analysis in the skin and blood of patients with parapsoriasis and early-stage mycosis fungoides. J Pathol 2002; 197:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/9\">",
"      Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides. J Am Acad Dermatol 2005; 53:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/10\">",
"      Erkek E, Sahin S, Atakan N, et al. Absence of Epstein-Barr virus and human herpesvirus-6 in pityriasis lichenoides and plaque parapsoriasis. J Eur Acad Dermatol Venereol 2002; 16:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/11\">",
"      Ballanger F, Bressollette C, Volteau C, et al. Cytomegalovirus: its potential role in the development of cutaneous T-cell lymphoma. Exp Dermatol 2009; 18:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/12\">",
"      Amitay-Laish I, Sarid R, Ben-Amitai D, et al. Human herpesvirus 8 is not detectable in lesions of large plaque parapsoriasis, and in early-stage sporadic, familial, and juvenile cases of mycosis fungoides. J Am Acad Dermatol 2012; 66:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/13\">",
"      Qu&eacute;reux G, Andr&eacute;-Garnier E, Knol AC, et al. Evaluation of the role of human herpes virus 6 and 8 in parapsoriasis. Exp Dermatol 2009; 18:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/14\">",
"      Kreuter A, Bischoff S, Skrygan M, et al. High association of human herpesvirus 8 in large-plaque parapsoriasis and mycosis fungoides. Arch Dermatol 2008; 144:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/15\">",
"      Trento E, Castilletti C, Ferraro C, et al. Human herpesvirus 8 infection in patients with cutaneous lymphoproliferative diseases. Arch Dermatol 2005; 141:1235.",
"     </a>",
"    </li>",
"    <li>",
"     Weedon D. Skin Pathology, 2nd ed, Churchill Livingstone, St. Louis 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/17\">",
"      Ross S, S&aacute;nchez JL. Parapsoriasis. A century later. Int J Dermatol 1990; 29:329.",
"     </a>",
"    </li>",
"    <li>",
"     Wood GS, Reizner G. Other papulosquamous disorders. In: Dermatology, 2nd ed, Bolognia JL, Jorizzo JL, Rapini RP (Eds), Elsevier, Spain 2008. Vol 1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/19\">",
"      Murphy M, Fullen D, Carlson JA. Low CD7 expression in benign and malignant cutaneous lymphocytic infiltrates: experience with an antibody reactive with paraffin-embedded tissue. Am J Dermatopathol 2002; 24:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/20\">",
"      Alaibac M, Pigozzi B, Belloni-Fortina A, et al. CD7 expression in reactive and malignant human skin T-lymphocytes. Anticancer Res 2003; 23:2707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/21\">",
"      Florell SR, Cessna M, Lundell RB, et al. Usefulness (or lack thereof) of immunophenotyping in atypical cutaneous T-cell infiltrates. Am J Clin Pathol 2006; 125:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/22\">",
"      Pigozzi B, Bordignon M, Belloni Fortina A, et al. Expression of the CD1a molecule in B- and T-lymphoproliferative skin conditions. Oncol Rep 2006; 15:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/23\">",
"      Zeybek ND, Asan E, Erbil AH, Dagdeviren A. Immunohistochemical analysis of small plaque parapsoriasis: involvement of dendritic cells. Acta Histochem 2008; 110:380.",
"     </a>",
"    </li>",
"    <li>",
"     Wood GS, Hu CH, Liu R. Parapsoriasis and pityriasis lichenoides. In: Fitzpatrick's Dermatology in General Medicine, 8th, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS.  (Eds), McGraw-Hill Medical, New York 2012. Vol 1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/25\">",
"      Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides. Experience in 79 patients. Arch Dermatol 1998; 134:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/26\">",
"      Zackheim HS. Treatment of patch-stage mycosis fungoides with topical corticosteroids. Dermatol Ther 2003; 16:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/27\">",
"      Takahashi H, Takahashi I, Tsuji H, et al. Digitate dermatosis successfully treated by narrowband ultraviolet B irradiation. J Dermatol 2011; 38:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/28\">",
"      Aydogan K, Karadogan SK, Tunali S, et al. Narrowband UVB phototherapy for small plaque parapsoriasis. J Eur Acad Dermatol Venereol 2006; 20:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/29\">",
"      Herzinger T, Degitz K, Plewig G, R&ouml;cken M. Treatment of small plaque parapsoriasis with narrow-band (311 nm) ultraviolet B: a retrospective study. Clin Exp Dermatol 2005; 30:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/30\">",
"      Hofer A, Cerroni L, Kerl H, Wolf P. Narrowband (311-nm) UV-B therapy for small plaque parapsoriasis and early-stage mycosis fungoides. Arch Dermatol 1999; 135:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/31\">",
"      Arai R, Horiguchi Y. Retrospective study of 24 patients with large or small plaque parapsoriasis treated with ultraviolet B therapy. J Dermatol 2012; 39:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/32\">",
"      Powell FC, Spiegel GT, Muller SA. Treatment of parapsoriasis and mycosis fungoides: the role of psoralen and long-wave ultraviolet light A (PUVA). Mayo Clin Proc 1984; 59:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/33\">",
"      Rosenbaum MM, Roenigk HH Jr, Caro WA, Esker A. Photochemotherapy in cutaneous T cell lymphoma and parapsoriasis en plaques. Long-term follow-up in forty-three patients. J Am Acad Dermatol 1985; 13:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/34\">",
"      Weberschock T, Strametz R, Lorenz M, et al. Interventions for mycosis fungoides. Cochrane Database Syst Rev 2012; 9:CD008946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/35\">",
"      Lindahl LM, Fenger-Gron M, Iversen L. Topical nitrogen mustard therapy in patients with mycosis fungoides or parapsoriasis. J Eur Acad Dermatol Venereol 2013; 27:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/36\">",
"      Zackheim HS, Epstein EH Jr, McNutt NS, et al. Topical carmustine (BCNU) for mycosis fungoides and related disorders: a 10-year experience. J Am Acad Dermatol 1983; 9:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20200/abstract/37\">",
"      Lazar AP, Caro WA, Roenigk HH Jr, Pinski KS. Parapsoriasis and mycosis fungoides: the Northwestern University experience, 1970 to 1985. J Am Acad Dermatol 1989; 21:919.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15284 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-7B7E1375F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_46_20200=[""].join("\n");
var outline_f19_46_20200=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11633062\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11633013\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88963253\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11633020\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H56547675\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11633027\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57288599\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H56547880\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11633041\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H799317\">",
"      Large plaque versus small plaque parapsoriasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10848393\">",
"      Small plaque parapsoriasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21277278\">",
"      Large plaque parapsoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11633048\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10848471\">",
"      Small plaque parapsoriasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H799408\">",
"      - Indications for treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3365268\">",
"      - Initial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3365384\">",
"      - Poor response to initial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3365143\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10848478\">",
"      Large plaque parapsoriasis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H109157996\">",
"      - General approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H57289237\">",
"      - Topical corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H57289244\">",
"      - Phototherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H57289251\">",
"      - Topical chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3365150\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11633055\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11633062\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/15284\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15284|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/55/26488\" title=\"picture 1A\">",
"      Small plaque parapsoriasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/20/17732\" title=\"picture 1B\">",
"      Small plaque parapsoriasis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/14/34022\" title=\"picture 1C\">",
"      Digitate dermatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/38/33376\" title=\"picture 2A\">",
"      Large plaque parapsoriasis 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/38/43616\" title=\"picture 2B\">",
"      Large plaque parapsoriasis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/12/32963\" title=\"picture 2C\">",
"      Parapsoriasis large plaque",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/14/23781\" title=\"picture 2D\">",
"      Parapsoriasis dark skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/50/19233\" title=\"picture 3\">",
"      Pityriasis lichenoides chronica",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/28/42433\" title=\"picture 4A\">",
"      Guttate psoriasis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/9/24725\" title=\"picture 4B\">",
"      Guttate psoriasis 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/61/35793\" title=\"picture 5A\">",
"      Pityriasis rosea with herald patch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/42/679\" title=\"picture 5B\">",
"      Herald patch dark skin 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/8/11394\" title=\"picture 6A\">",
"      Nummular eczema legs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/46/38626\" title=\"picture 6B\">",
"      Nummular eczema legs 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/35/44600\" title=\"picture 7\">",
"      Skin biopsy MF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/2/24615\" title=\"picture 8\">",
"      Chronic ACD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/0/19463\" title=\"picture 9A\">",
"      Plaque psoriasis 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/44/16071\" title=\"picture 9B\">",
"      Plaque psoriasis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/41/29337\" title=\"picture 9C\">",
"      Plaque psoriasis 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/7/15474\" title=\"picture 10\">",
"      Nail psoriasis pits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/15284|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 1\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11943?source=related_link\">",
"      Clinical features and diagnosis of allergic contact dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27625?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=related_link\">",
"      General principles of dermatologic therapy and topical corticosteroid use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/29/32216?source=related_link\">",
"      Guttate psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7546?source=related_link\">",
"      Lymphomatoid papulosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=related_link\">",
"      Overview of dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/61/17369?source=related_link\">",
"      Pityriasis lichenoides et varioliformis acuta (PLEVA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/35/18999?source=related_link\">",
"      Pityriasis rosea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33160?source=related_link\">",
"      Psoralen plus ultraviolet A (PUVA) photochemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=related_link\">",
"      Skin biopsy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17017?source=related_link\">",
"      Treatment of early stage (IA to IIA) mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26775?source=related_link\">",
"      UVB therapy (broadband and narrowband)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_46_20201="Hypospadias TIP repair";
var content_f19_46_20201=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69788&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69788&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 557px\">",
"   <div class=\"ttl\">",
"    Hypospadias TIP repair (Tubularized urethroplasty with or without incision of the urethra plate)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 537px; height: 705px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Proximal hypospadias with a stent in the abnormal urethral meatus. Note the location of the abnormal urethral meatus at the penoscrotal junction. In the initial dissection, a ventral strip of skin (the urethral plate) has been preserved on the penile shaft. B) In this case, the urethral plate is adequate in width and, therefore, is reconstructed into a tube over the stent, bringing the new urethral meatus to a normal position at the tip of the glans penis. C) If the urethral plate is not wide enough to be reconstructed into an adequate tube, then the plate can be incised with a relaxing incision, and then sewn into an adequate tube. The raw area that is incised will undergo epithelization during the healing process. D) The glans penis is reconstructed, and subcutaneous tissue is used to cover the urethra with extra layers to prevent fistula formation. E) The extra dorsal skin is trimmed and sewn together to complete the hypospadias repair.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Transverse Preputial Onlay Island Flap. In: Hinman's Atlas of Pediatric Urologic Surgery, 2nd ed, Hinman F, Baskin LS (Eds), Elsevier, Oxford 2008. Copyright &copy; 2008. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_46_20201=[""].join("\n");
var outline_f19_46_20201=null;
var title_f19_46_20202="Hypertension in dialysis patients";
var content_f19_46_20202=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hypertension in dialysis patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/46/20202/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/46/20202/contributors\">",
"     William L Henrich, MD, MACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/46/20202/contributors\">",
"     Lionel U Mailloux, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/46/20202/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/46/20202/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/46/20202/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/46/20202/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/46/20202/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/46/20202/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several major issues to consider when approaching hypertension in dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      What is the pathogenesis of the elevation in blood pressure (BP)?",
"     </li>",
"     <li>",
"      How is hypertension best defined?",
"     </li>",
"     <li>",
"      What are the target blood pressure goals?",
"     </li>",
"     <li>",
"      How should the hypertension be treated?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic review will present the epidemiology, pathogenesis, and treatment of hypertension in dialysis patients, with an emphasis on hypertension in patients undergoing hemodialysis. Most patients undergoing peritoneal dialysis can become normotensive with strict adherence to volume control, unless there are difficulties attaining effective ultrafiltration. This problem is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23337?source=see_link\">",
"     \"Problems with solute clearance and ultrafiltration in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is a common finding in dialysis patients. Based upon multiple studies, over 50 to 60 percent of hemodialysis patients (up to 85 percent in some reports) and nearly 30 percent peritoneal dialysis patients are hypertensive [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. These values are lower than the 80 percent incidence of hypertension at the initiation of dialysis, due largely to better volume control in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians should strive for an even better blood pressure control rate [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/1\">",
"     1",
"    </a>",
"    ]. Since poorly controlled hypertensive hemodialysis patients are more likely to have large interdialytic and excessive weight gains, persistent hypertension often reflects volume control that remains imperfect despite the initiation of dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/4,7\">",
"     4,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Poor blood pressure control has also been reported in children undergoing dialysis. In one study, approximately one-half of children had uncontrolled hypertension after one year of dialysis therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cardiovascular risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between hypertension and cardiovascular mortality in patients with end-stage renal disease is complicated because of the high prevalence of comorbid conditions and underlying vascular pathology. Although a positive correlation has been found in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/9-11\">",
"     9-11",
"    </a>",
"    ], a few reports in which patient outcomes were assessed for only one to two years have found little or no relationship between hypertension and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Enhanced mortality has also been reported among prevalent dialysis patients with the lowest blood pressures who were followed for short periods [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/12-16\">",
"     12-16",
"    </a>",
"    ]. This was shown in the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a cohort study of 40,933 hemodialysis patients followed for a 15 month period, the hazard ratio for all cause death for a predialysis systolic blood pressure &lt;110 mmHg was 1.60, while the ratio for a predialysis diastolic blood pressures &lt;50 mmHg was 2.00 [",
"      <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second cohort study of 16,939 patients found that a low systolic blood pressure (&lt;120 mmHg) was associated with an increased mortality with follow-up of one to two years [",
"      <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/15\">",
"       15",
"      </a>",
"      ]; by comparison, an increased mortality after three years was observed in those with systolic blood pressures greater than 150 mmHg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The short follow-up period of most of the studies showing a negative correlation may be inadequate since an elevated blood pressure must be present for a sufficient time period to contribute to cardiovascular disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mortality and patients with lower pressures may represent a sicker population [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/17\">",
"     17",
"    </a>",
"    ]. Improved survival and better cardiovascular outcomes due to adequate blood pressure control have been demonstrated in those studies with the longest duration of follow-up and with the best design (including adequate control for baseline cardiac parameters) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/16,18-20\">",
"     16,18-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the period of follow-up, a number of additional factors can affect the general correlation between elevated blood pressure and lower survival among dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Enhanced mortality among those with lower blood pressures may be a result of myocardial dysfunction, extensive comorbid conditions,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      poor nutrition. This was shown in a retrospective study of 2770 peritoneal dialysis patients, which found that greater blood pressure levels were protective against mortality at one year among all patients [",
"      <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/16\">",
"       16",
"      </a>",
"      ]. By comparison, there was increased mortality at one year among the nearly 600 patients with increased blood pressure who were placed on the transplant wait list within six months of initiating dialysis. This suggests that the general correlation between elevated blood pressure and lower survival can also be observed among healthier dialysis patients, even with a short period of follow-up.",
"     </li>",
"     <li>",
"      The relationship between hypertension and vascular disease may be dissociated since, because of swings in volume status and the effects of hemodialysis, a wide range of blood pressures are observed in individuals as well as the dialysis population.",
"     </li>",
"     <li>",
"      Elevated blood pressure alone fails to account for the possible deleterious effect of an increased pulse pressure, which is defined as the systolic minus diastolic pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. A retrospective study of over 44,000 dialysis patients found that an increased pulse pressure directly increased the risk of mortality at one year follow-up, even after adjustment for the systolic blood pressure alone [",
"      <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/12/26823?source=see_link\">",
"       \"Increased pulse pressure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A higher mortality may be due to the presence of left ventricular hypertrophy (on ECG or echocardiography), which is associated with increases in the incidence of heart failure, ventricular arrhythmias, death following myocardial infarction, sudden cardiac death, aortic root dilation, and a cerebrovascular event. Some evidence suggests that partial regression of hypertrophy due to adequate hypertensive therapy lowers the risk of mortality among dialysis patients [",
"      <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17959?source=see_link\">",
"       \"Clinical implications and treatment of left ventricular hypertrophy in hypertension\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are conflicting data concerning a possible loss of the usual diurnal variation in BP in end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. To the degree that some patients may have a diminution of the expected decline in BP during the night (or even nocturnal hypertension) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/25\">",
"     25",
"    </a>",
"    ], it may be erroneous to conclude that a \"borderline\" daytime blood pressure is actually lower the rest of the day. This loss of dipping, termed nocturnal hypertension, is associated with an increased risk of adverse cardiovascular outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of hypertension in end-stage renal disease is multifactorial, as one or more of the following factors play a role in individual patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/6,28,29\">",
"     6,28,29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sodium and volume excess due to diminished sodium excretory capacity. Accumulating evidence, for example, suggests that patients on chronic ambulatory peritoneal dialysis may become hypertensive after many years, possibly because of the loss in part of ultrafiltrating capacity by the peritoneal membrane [",
"      <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/30-35\">",
"       30-35",
"      </a>",
"      ]. A decrease in dialysate sodium may also be associated with a decrease in blood pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Activation of the renin-angiotensin-aldosterone system due to primary vascular disease or to regional ischemia induced by scarring.",
"     </li>",
"     <li>",
"      Increased activity of the sympathetic nervous system.",
"     </li>",
"     <li>",
"      An increase in endothelium-derived vasoconstrictors (such as endothelin) or a reduction in endothelium-derived vasodilators (such as nitric oxide).",
"     </li>",
"     <li>",
"      The administration of erythropoietin.",
"     </li>",
"     <li>",
"      An increase in intracellular calcium induced by parathyroid hormone excess [",
"      <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/37\">",
"       37",
"      </a>",
"      ]. The observation that correction of hyperparathyroidism via either vitamin D administration or parathyroidectomy lowers the blood pressure is compatible with this hypothesis [",
"      <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. In one report, the mean systolic pressure fell over a period of months by a mean of 9 mmHg after parathyroidectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Calcification of the arterial tree.",
"     </li>",
"     <li>",
"      Preexistent essential hypertension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Volume overload",
"    </span>",
"    &nbsp;&mdash;&nbsp;Volume expansion is perhaps the major factor in the development of hypertension in dialyzed patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/39\">",
"     39",
"    </a>",
"    ]. It leads to an elevation in BP via the combination of a rise in cardiac output and an inappropriately high systemic vascular resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/6,28\">",
"     6,28",
"    </a>",
"    ]. The latter finding may result from activation of the renin-angiotensin system or from the secretion of ouabain-like inhibitors of Na-K-ATPase, leading to elevations in intracellular sodium and calcium. The rise in cell calcium in vascular smooth muscle cells can then induce vasoconstriction.",
"   </p>",
"   <p>",
"    Regardless of the mechanism, removal of the excess sodium and attainment of \"dry weight\" (see below) can result in the normalization of BP in more than 60 percent of hemodialysis-dependent patients and nearly all patients undergoing peritoneal dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/6,40-45\">",
"     6,40-45",
"    </a>",
"    ]. The degree of extracellular volume expansion may be insufficient to induce edema; thus, the absence of edema does not exclude hypervolemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Increased sympathetic activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sympathetic overactivity is a common finding in end-stage renal disease, correlating with the increase in both vascular resistance and systemic BP [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/46\">",
"     46",
"    </a>",
"    ]. The mechanism by which this occurs is unclear, but the afferent signal may arise within the kidney, since sympathetic activation is not seen in anephric patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/46\">",
"     46",
"    </a>",
"    ]. It has therefore been proposed that activation of chemoreceptors",
"    <strong>",
"     within the kidney",
"    </strong>",
"    by uremic metabolites may play an important role. Activation of these chemoreceptors leads to a neural reflex that traverses afferent pathways to the central nervous system, resulting in increased efferent sympathetic tone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Altered endothelial cell function",
"    </span>",
"    &nbsp;&mdash;&nbsp;An intriguing concept regarding the pathogenesis of hypertension in end-stage renal disease is abnormal endothelial release of hemodynamically active compounds. As an example, elevated plasma levels of the potent vasoconstrictor endothelin-1 have been found in uremic subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. The concentration of other endothelin isoforms also may be increased, but only endothelin-1 has been linked to high BP [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It should be appreciated, however, that these observations do not prove a cause and effect relationship. The development of a method to inhibit the activity of endothelin (such as a receptor blocker) will be necessary to determine the physiologic importance of endothelin in these patients.",
"   </p>",
"   <p>",
"    The endothelium also produces vasodilators, such as prostacyclin and nitric oxide (NO or endothelium-derived relaxing factor). NO is a synthetic product of L-arginine in endothelial cells and is a potent vasodilator. There is evidence that uremic plasma contains a higher level of an endogenous compound &mdash; asymmetrical dimethylarginine &mdash; that is an inhibitor of NO synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/50\">",
"     50",
"    </a>",
"    ]. This observation raises the possibility that NO deficiency may contribute to the development of hypertension in end-stage renal disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Erythropoietin",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increase in BP of 10 mmHg or more may occur in patients with renal failure who are treated with erythropoietin. The risk is greatest in those with rapid correction of severe anemia and with preexistent hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8436?source=see_link\">",
"     \"Hypertension following erythropoietin in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     METHOD OF BLOOD PRESSURE MEASUREMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A reliance upon immediate predialysis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    postdialysis BP measurements alone to detect hypertension in patients undergoing hemodialysis may be misleading. The predialysis systolic BP may overestimate the mean interdialytic SBP by 10 mmHg, while the postdialysis systolic BP may underestimate the mean systolic BP by 7 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/51\">",
"     51",
"    </a>",
"    ]. Some studies, however, have suggested that the postdialysis BP may be more reflective of interdialytic BP [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Continuous monitoring is therefore warranted in patients suspected of poor control (such as those with large interdialytic weight gain) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/25,54-57\">",
"     25,54-57",
"    </a>",
"    ]. The results with ambulatory blood pressure monitoring appear to be relatively reproducible [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/56,58\">",
"     56,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ambulatory BP monitoring may also be useful in determining the \"systolic load,\" which is the amount of time the systolic pressure exceeds 140 mmHg during the day [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/25,59-61\">",
"     25,59-61",
"    </a>",
"    ]. This load may be an important factor in the development of left ventricular hypertrophy. The ambulatory BP is also associated with significant prognostic value [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/59\">",
"     59",
"    </a>",
"    ]. Interdialytic hypertension does not appear to be a problem with the Tassin and nocturnal hemodialysis regimens of long, slow dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Home blood pressure monitoring may also improve hypertension detection and prognostic value [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/60,63\">",
"     60,63",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, the finding of an average systolic BP greater than 150 mmHg at home was more accurate than conventional blood pressure monitoring in helping diagnose hypertension (as determined by ambulatory BP) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The best prognosis was observed with a home measurement of a systolic blood pressure of 125 to 145 mmHg [",
"      <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Uremic patients have an additional problem in that they lose the usual diurnal variation in blood pressure, possibly leading to nocturnal hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/25\">",
"     25",
"    </a>",
"    ]. Thus, even patients thought to be well controlled with daytime BP measurements may still be at risk for hypertension-induced cardiovascular morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/64\">",
"     64",
"    </a>",
"    ]. This problem should be suspected if, for example, left ventricular mass increases (on echocardiography) despite seemingly adequate control of hypertension and anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26584?source=see_link\">",
"     \"Myocardial dysfunction in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     OPTIMAL BLOOD PRESSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current blood pressure target ranges for dialysis patients have been extrapolated from those suggested for the non-dialysis patient population. There have been no randomized prospective trials evaluating the target blood pressure in dialysis patients. In general, the targeting of blood pressure goals (whether to a specific level or below a certain value) should ideally be set individually based upon the patient's cardiac and neurologic status, comorbid conditions, age, and other clinical factors [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For some dialysis patients, we suggest that goal BP levels be a predialysis value of below",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg and a postdialysis value of below",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/19,41,65-68\">",
"     19,41,65-68",
"    </a>",
"    ]. If clinical characteristics permit and ambulatory pressures are measured, a \"normal\" BP, defined as a mean ambulatory BP less than",
"    <span class=\"nowrap\">",
"     135/85",
"    </span>",
"    mmHg during the day and less than",
"    <span class=\"nowrap\">",
"     120/80",
"    </span>",
"    mmHg by night, is a reasonable target.",
"   </p>",
"   <p>",
"    However, controversy exists over the blood pressure target; some investigators have postulated that excessively low systemic pressures lead to enhanced mortality (a so-called J- or U-shaped curve) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/13,69-73\">",
"     13,69-73",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A report of nearly 4500 hemodialysis patients found a significantly increased adjusted mortality risk among patients with a low predialysis systolic pressure (&lt;110 mmHg); risk was also increased in patients with high postdialysis diastolic (&gt;110 mmHg) and systolic pressures (&gt;180 mmHg) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an observational study of 56,338 and 69,590 incident and prevalent hemodialysis patients, respectively, a markedly increased risk of death was noted among those with systolic blood pressures less than 120 mmHg versus those with systolic blood pressures between 160 and 180 mmHg (hazard ratio of 2.63 to 3.68 based upon different statistical adjustments) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective analysis of 13,792 incident hemodialysis patients evaluated the correlation between survival and achieving",
"      <span class=\"nowrap\">",
"       K/DOQI",
"      </span>",
"      clinical practice guidelines for multiple parameters [",
"      <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/72\">",
"       72",
"      </a>",
"      ]. An increased mortality was associated with achieving the goal predialysis blood pressure of less than",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg (1.90, 95% CI 1.73-2.10).",
"     </li>",
"     <li>",
"      Lower blood pressures are associated with a higher risk of hemoaccess thrombosis [",
"      <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/74-76\">",
"       74-76",
"      </a>",
"      ]. In a secondary analysis of the HEMO study in which 2005 episodes of vascular thrombosis were reported for 1426 subjects, there was a modest increase in the relative risk of thrombosis for each standard deviation decrease below the mean predialysis systolic pressure, even after controlling for intradialytic hypotension [",
"      <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An analysis of 24,525 patients included in the Dialysis Outcomes and Practice Patterns Study (DOPPS) showed that, compared with a predialysis systolic blood pressure of 130 to 159 mmHg, mortality was higher in facilities with 20 percent more patients with systolic blood pressures of 110 to 129 mmHg [",
"      <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/73\">",
"       73",
"      </a>",
"      ]. This study also showed higher mortality in facilities with 20 percent more patients with systolic blood pressures &ge;160 mmHg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether these results are due to a direct effect of a relatively low blood pressure or to an associated comorbid condition is unclear, since the worse outcomes at lower pressures could reflect worse underlying disease.",
"   </p>",
"   <p>",
"    In summary, the target goals should generally be based upon individual patient characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/1\">",
"     1",
"    </a>",
"    ]. In some younger patients, the target BP may even be set as low as",
"    <span class=\"nowrap\">",
"     120/80",
"    </span>",
"    mmHg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Control of volume status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Control of volume status can either normalize the BP or make the hypertension easier to control in the great majority of dialysis patients. Nearly all peritoneal dialysis patients, for example, can become normotensive with strict adherence to volume control [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/43,77\">",
"     43,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Avoidance of large weight gains in the interdialytic period is clearly desirable. To achieve this goal, patients should adhere to a restricted salt diet (750 to 1000 mg of",
"    <span class=\"nowrap\">",
"     sodium/day),",
"    </span>",
"    which also helps decrease thirst [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/19,78,79\">",
"     19,78,79",
"    </a>",
"    ]. However, patient compliance is often suboptimal.",
"   </p>",
"   <p>",
"    As a result, heavy reliance is placed on the dialysis procedure to gradually remove fluid over a period of days to weeks until a stable \"dry weight\" is achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/6,19,40,41,66,68,80-83\">",
"     6,19,40,41,66,68,80-83",
"    </a>",
"    ]. The exact definition of dry weight remains uncertain, but multiple definitions have been advanced. As examples, dry weight has been defined clinically as that weight at which:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Either the BP has normalized or symptoms of hypovolemia appear, not merely the absence of edema.",
"     </li>",
"     <li>",
"      The seated BP is optimized, and symptomatic orthostatic hypotension and clinical fluid overload are not present postdialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      At the end of dialysis, the patient remains normotensive until the next dialysis without antihypertensive medication [",
"      <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Numerous attempts have been made to utilize alternative methods to more accurately assess dry weight. These include bioimpedance plethysmography, and measurement of the inferior cava diameter, plasma natriuretic peptide (particularly atrial and brain) concentrations, blood volume, and other parameters. However, these methods are frequently impractical, are not necessarily accurate, and a large prospective study has not yet been performed that compares these methods to clinical assessment alone [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/86-89\">",
"     86-89",
"    </a>",
"    ]. The clinician must therefore define the dry weight and goal blood pressure for each dialysis patient based upon his or her best judgment.",
"   </p>",
"   <p>",
"    Unfortunately, one problem with a reliance upon a clinical assessment of volume status is that volume expansion may persist even among those thought to have attained dry weight. This possibility was illustrated in a report in which the blood volume, inferior vena cava diameter, and posthemodialysis dry weight were evaluated in 35 stable hemodialysis patients (17 with and 18 without hypertension, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/90\">",
"     90",
"    </a>",
"    ]. Despite the attainment of dry weight as determined by traditional clinical standards, the blood volume of hypertensive patients was significantly higher than in normotensive patients both before (3.53 versus 2.82",
"    <span class=\"nowrap\">",
"     L/m2)",
"    </span>",
"    and after (2.88 and 2.49",
"    <span class=\"nowrap\">",
"     L/m2)",
"    </span>",
"    dialysis. In this study, the timing of the postdialysis inferior vena cava measurement was critical, since many hours are required to reconstitute the plasma volume and intravascular compartment. By comparison, other studies are flawed by too early a determination [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The view that volume expansion underlies the inability to control blood pressure in many hemodialysis patients is supported by studies that rely upon plasma atrial natriuretic peptide (ANP) concentrations to help assess the extracellular volume [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. One study, for example, measured predialysis and postdialysis ANP values [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/92\">",
"     92",
"    </a>",
"    ]. Predialysis levels were markedly elevated in the hypertensive patients compared to those who were normotensive; in addition, the postdialysis ANP concentrations normalized in those with dialysis-sensitive hypertension but were unchanged in those with dialysis-resistant hypertension. In general, although predialysis ANP values may correlate with volume overload, postdialysis levels are unreliable in determining dry weight [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two other factors may limit the degree of fluid removal by predisposing to episodes of hypotension (and therefore the need for volume replacement) during the hemodialysis procedure: antihypertensive drugs; and rapid fluid removal required by shorter dialysis times. Thus, tapering drug therapy and gradual fluid removal may be beneficial in patients in whom hypotension during dialysis prevents the attainment of dry weight and a normal BP.",
"   </p>",
"   <p>",
"    Chronic volume overload also may be due to the chronic dialysate sodium prescription. Dialysate sodium prescriptions are relatively higher than that observed in most dialysis patients, leading to decreased sodium loss during dialysis and mild increases in serum sodium values post-dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/94\">",
"     94",
"    </a>",
"    ]. This results in volume overload and increased thirst, thereby increased blood pressure. To help avoid these, some advocate an individualized approach to the dialysate sodium prescription.",
"   </p>",
"   <p>",
"    Among patients initiated on dialysis, a period of time must ensue between the attainment of dry weight and adequate control of blood pressure, a property termed the lag phenomenon [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/95\">",
"     95",
"    </a>",
"    ]. This reflects the time required to convert the patient from a catabolic to an anabolic state, a period in which the extracellular fluid space slowly stabilizes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/95\">",
"     95",
"    </a>",
"    ]. A similar phenomenon has been observed with the use of diuretics for the treatment of hypertension in the patient without renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Prolonged and/or more frequent hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients in a large dialysis center in Tassin, France and some home hemodialysis patients undergo long, slow hemodialysis in which the standard regimen is eight hours, three times per week. This regimen is associated with the maintenance of normotension without medications in almost all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/41,62,97,98\">",
"     41,62,97,98",
"    </a>",
"    ]. Although these results have been largely attributed to optimal volume control, other factors may also contribute, such as more complete control of uremia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/62\">",
"     62",
"    </a>",
"    ] which, as noted above, may decrease afferent renal nerve activity and efferent sympathetic activation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/46\">",
"     46",
"    </a>",
"    ]. A subset of these patients, for example, is normotensive despite the presence of increased extracellular fluid volume while having achieved clinical dry weight [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/99\">",
"     99",
"    </a>",
"    ]. The reason for this observation is unclear. This regimen, which is not widely used, is also associated with a high patient survival rate [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=see_link&amp;anchor=H12#H12\">",
"     \"Patient survival and maintenance dialysis\", section on 'Adequacy of dialysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nocturnal hemodialysis, a procedure in which dialysis is performed six or seven nights a week during sleep for a variable amount of time based upon the length of sleep desired (usually 6 to 12 hours in total), is also associated with excellent blood pressure control [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/100\">",
"     100",
"    </a>",
"    ]. Almost all patients become normotensive without medications. To achieve this, the \"target weight\" is progressively decreased until all antihypertensive agents are discontinued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/264?source=see_link\">",
"     \"Technical aspects of nocturnal hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some studies also suggest that more frequent hemodialysis treatments, via short daily hemodialysis, may also be associated with normotension without medications and with regression of left ventricular hypertrophy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18137?source=see_link\">",
"     \"Short daily hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2007 European Best Practice Guidelines recommend that the treatment time",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    frequency of dialysis should be increased in patients with hypertension despite optimal volume removal [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Antihypertensive medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy with antihypertensive drugs is primarily indicated in the 25 to 30 percent of dialysis patients in whom hypertension persists despite seemingly adequate volume control. Some evidence suggests that the administration of such agents may provide significant clinical benefits, including improved mortality.",
"   </p>",
"   <p>",
"    A 2009 systematic review and meta-analysis of eight randomized controlled trials (three with and five without hypertensive patients) that enrolled 1679 dialysis patients found that lowering blood pressure with antihypertensive therapy was associated with decreased risks of cardiovascular events (RR of 0.71, 95% CI 0.55-0.92), all cause mortality (RR 0.80, 0.66-0.96) and cardiovascular mortality (0.71, 0.50-0.99) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/102\">",
"     102",
"    </a>",
"    ]. Although there was significant variation in attained blood pressure, the overall mean decrease in systolic and diastolic blood pressure with active therapy was 4 to 5 mmHg and 2 to 3 mmHg, respectively. There were no studies that compared the efficacy of different antihypertensive agents; the relative effects of ARBs, ACE inhibitors, beta blockers, and calcium blockers were largely compared with placebo or conventional therapy. Additional limitations included the low number of patients (including those with hypertension), lack of information concerning volume control, and marked variations in blood pressure reduction (due in part to absence of firm criteria for measurement) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these limitations, it generally appears that renin-angiotensin-system blockers, beta blockers, and calcium-channel blockers provide similar efficacy in dialysis patients. Thus, the type of antihypertensive therapy chosen is dictated in part by coexistent diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, several points about specific classes of antihypertensive drugs deserve emphasis, as discussed in the following sections [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/66,104\">",
"     66,104",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium channel blockers are both effective and well tolerated in dialysis patients, even in those who are volume expanded [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/64\">",
"     64",
"    </a>",
"    ]. The only randomized prospective study found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    , compared with placebo, improved overall mortality among hypertensive dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Calcium channel blockers are particularly useful in patients with left ventricular hypertrophy and diastolic dysfunction. Calcium channel blockers do not require supplementary postdialysis dosing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     ACE inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibitors are well tolerated and are particularly effective in patients with heart failure due to systolic dysfunction and in many patients after an acute myocardial infarction. The 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines also suggest that these agents",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    angiotensin II receptor blockers are preferred in dialysis patients with significant residual renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/106\">",
"     106",
"    </a>",
"    ]. These agents may help preserve native kidney function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13175?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ACE inhibitors (and angiotensin II receptor blockers [ARBs], see next section) are associated with a decrease in left ventricular mass among hemodialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/107,108\">",
"     107,108",
"    </a>",
"    ]. There are conflicting data concerning the effect of ACE inhibitors on mortality among hypertensive patients undergoing maintenance dialysis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized prospective study found no survival benefit with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/30/16872?source=see_link\">",
"       fosinopril",
"      </a>",
"      among hemodialysis patients with left ventricular hypertrophy [",
"      <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/109\">",
"       109",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A possible mortality benefit was shown in an observational study in which hypertensive dialysis patients were administered antihypertensive regimens with or without ACE inhibitors (60 and 66 patients, respectively) at the discretion of the physician [",
"      <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/110\">",
"       110",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective cohort study of 1950 dialysis patients who were newly treated with ACE",
"      <span class=\"nowrap\">",
"       inhibitors/ARBs",
"      </span>",
"      versus calcium channel blockers or statins found no ACE",
"      <span class=\"nowrap\">",
"       inhibitor/ARB-associated",
"      </span>",
"      reduction in a composite outcome including all-cause mortality",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hospitalization from myocardial infarction, stroke, heart failure or revascularization [",
"      <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/111\">",
"       111",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ACE inhibitors have unique side effects in end-stage renal disease: they can interfere with the action of erythropoietin; and they can trigger an anaphylactoid reaction (possibly mediated by kinins) in patients dialyzed with an AN69 dialyzer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=see_link&amp;anchor=H8#H8\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\", section on 'Angioedema and anaphylactoid reactions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4295?source=see_link\">",
"     \"Reactions to the hemodialysis membrane\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of ACE inhibitors on erythropoiesis has been best described in renal transplant recipients with erythrocytosis. In this setting, an ACE inhibitor can lower the hematocrit toward normal in almost all patients. This can occur by reducing the secretion or interfering with the action of EPO, including those receiving EPO supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/112,113\">",
"     112,113",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10857?source=see_link\">",
"     \"Erythrocytosis following renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are less consistent data concerning the effect of ACE inhibitors on erythropoietin doses in dialysis patients. Increased dose requirements and no effects have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/114\">",
"     114",
"    </a>",
"    ]. There is also an increased risk of hyperkalemia among chronic hemodialysis patients treated with an ACE inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/114\">",
"     114",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=see_link\">",
"     \"Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     ARBs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of angiotensin II receptor blockers (ARBs) are currently available. Among hemodialysis patients, ARBs (and ACE inhibitors) are associated with a decrease in left ventricular mass [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/108\">",
"     108",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25224?source=see_link\">",
"     \"Renin-angiotensin system inhibition in the treatment of hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is limited experience with ARBs in patients with hypertension and end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/114,115\">",
"     114,115",
"    </a>",
"    ]. In one open-label trial, 360 hypertensive dialysis patients were randomly assigned to an ARB or no ARB [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/115\">",
"     115",
"    </a>",
"    ]. After multivariate adjustment, ARBs significantly reduced fatal and nonfatal cardiovascular disease events (hazard ratio 0.5, 95% CI 0.33-0.79). The most common adverse event was heart failure (fatal and nonfatal), with ARBs lowering the rate by one-half.",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines suggest that these agents",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ACE inhibitors are preferred in dialysis patients with hypertension and significant residual renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/106\">",
"     106",
"    </a>",
"    ]. These agents may help preserve native kidney function.",
"   </p>",
"   <p>",
"    ARBS and ACE inhibitors have similar issues in terms of adverse effects, including hyperkalemia and possible dampened erythropoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/114\">",
"     114",
"    </a>",
"    ]. In addition, although ARBs do not affect bradykinin levels, anaphylactoid reactions have been reported among patients receiving ARBS during hemodialysis with AN69 membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/116,117\">",
"     116,117",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4295?source=see_link\">",
"     \"Reactions to the hemodialysis membrane\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers are particularly indicated in patients who have had a recent myocardial infarction. As in nonuremic subjects, patients with end-stage renal disease who have heart failure due to systolic dysfunction may also benefit from therapy with a beta blocker. Such therapy should be initiated at very low doses to minimize the risk of hemodynamic deterioration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26584?source=see_link\">",
"     \"Myocardial dysfunction in end-stage renal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potential side effects include central nervous system depression (an effect that may be more prominent with lipid-soluble drugs that cross the blood-brain barrier), hyperkalemia (particularly with non-selective beta blockers), bradycardia, and possible exacerbation of heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/114\">",
"     114",
"    </a>",
"    ]. In addition, beta blockers should be used cautiously in patients also taking a calcium channel blocker, since there are often additive negative chronotropic and inotropic actions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Central sympathetic agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The central sympathetic agonists, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"     methyldopa",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    , are used less frequently because of their adverse effects involving the central nervous system. Some physicians have found clonidine patches to be effective and well tolerated, but this is not a universal finding [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/114,118\">",
"     114,118",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Reduced dialysate sodium concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variable dialysate sodium concentration may result in lower antihypertensive medication requirements and decreased postdialysis blood pressure. A randomized crossover study, for example, evaluated the antihypertensive effects of a programmed decrease in sodium dialysate concentration from 155 to 135",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (the last half hour was held constant at 135",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    compared with the standard stable sodium dialysate concentration of 140",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/119\">",
"     119",
"    </a>",
"    ]. Postdialysis blood pressure",
"    <span class=\"nowrap\">",
"     (133/69",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     126/66,",
"    </span>",
"    p&lt;0.05), postdialysis standing blood pressure, and drug usage were all reduced when patients were dialyzed with a variable sodium prescription. Although these benefits will require confirmation in further studies, a variable sodium protocol may be tried in selected hypertensive patients who do not respond well to other modalities.",
"   </p>",
"   <p>",
"    A fixed lower dialysate sodium concentration in combination with dietary salt restriction may also help control hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/120\">",
"     120",
"    </a>",
"    ]. In a preliminary uncontrolled study, for example, eight hypertensive hemodialysis patients were dialyzed against a gradually lowered sodium dialysate concentration (140 to 135",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    at a rate of 1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    every three to four weeks) and were encouraged to limit salt intake to less than 6",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/120\">",
"     120",
"    </a>",
"    ]. At study end, the mean arterial pressure was significantly lower (98 versus 108 mmHg, p=0.02), and antihypertensive medications were no longer required in four patients. However, adherence to this diet was difficult and the frequency of muscle cramps during dialysis was increased. This regimen also engenders the risk of episodic hypotension, and should be instituted very cautiously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Refractory hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some dialysis patients are resistant to both volume control and antihypertensive medications. Factors to be considered in this setting are concurrent use of a medication that can raise the BP (such as nonsteroidal antiinflammatory drugs), renovascular hypertension, noncompliance to medical regimen, and expanding cyst size in polycystic kidney disease. If a treatable cause cannot be found,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    may be effective in reducing the BP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42674?source=see_link\">",
"     \"NSAIDs and acetaminophen: Effects on blood pressure and hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33433?source=see_link\">",
"     \"Chronic kidney disease associated with atherosclerotic renovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/55/30582?source=see_link\">",
"     \"Hypertension in autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronically noncompliant hypertensive patients who refuse to take medications at home may benefit by the administration of long-acting antihypertensive medications in the dialysis unit. This was shown in a single center study of 16 patients in whom such a regimen (consisting of some combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transdermal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    based upon patient clinical characteristics) lowered the predialysis systolic and diastolic blood pressures by 15 and 12 mmHg, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients undergoing hemodialysis who are noncompliant and in whom volume status and hypertension cannot be controlled may also benefit by switching to peritoneal dialysis. Nearly all peritoneal dialysis patients can become normotensive with strict adherence to volume control [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/43\">",
"     43",
"    </a>",
"    ]. The efficacy of peritoneal dialysis in controlling blood pressure in refractory patients is related to its smoother volume removal and its more consistent maintenance of dry weight [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/43,45,121-123\">",
"     43,45,121-123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peritoneal dialysis is associated with lower systolic blood pressures than hemodialysis in most, but not all, studies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/25,51\">",
"     25,51",
"    </a>",
"    ], except for the use of long hemodialysis sessions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/41,62\">",
"     41,62",
"    </a>",
"    ]. As previously mentioned, long and slow hemodialysis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nocturnal hemodialysis have been associated with the attainment of normotension on no antihypertensive medications in almost all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/62\">",
"     62",
"    </a>",
"    ]. These regimens lead to better fluid control and better removal of uremic metabolites, which might decrease renal afferent nerve activity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/264?source=see_link\">",
"     \"Technical aspects of nocturnal hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bilateral nephrectomy may be considered in the rare noncompliant individual with life-threatening hypertension unable to be controlled with any dialysis modality. In one study, a significant decrease in blood pressure was observed three to six months after nephrectomy with six patients having a diastolic pressure of less than 90 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/124\">",
"     124",
"    </a>",
"    ]. One patient had persistent increases in blood pressure due largely to excess fluid intake between dialysis treatments, thereby further supporting the hypothesis that hypervolemia is highly significant in the pathogenesis of hypertension among dialysis patients. Bilateral nephrectomy is now largely abandoned, but was infrequently used for blood pressure control when potent antihypertensive agents were not yet widely available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     HYPERTENSION DURING HEMODIALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although hypotension during hemodialysis is a frequent complication, some patients develop paradoxical hypertension in the later stages of dialysis, a time at which most of the excess fluid has already been removed. This problem is intermittent in a given patient with a widely variable frequency. The pathogenesis is unclear, although some evidence suggests that altered nitric",
"    <span class=\"nowrap\">",
"     oxide/endothelin-1",
"    </span>",
"    balance",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    endothelial dysfunction may contribute [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/125,126\">",
"     125,126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal therapy of this problem is not known. In our experience, various medical modalities (such as the administration of an angiotensin converting enzyme inhibitor or an alpha-blocker at the time of hypertension, or pretreatment with antihypertensive medications to lower the blood pressure before dialysis) have not been predictably effective. We have had some success with the administration of isotonic saline to presumably treat hypovolemia-induced but excessive reflex sympathetic activation.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/22/9577?source=see_link\">",
"     Carvedilol",
"    </a>",
"    , which blocks endothelin-1 release, appears to be effective in this setting. This was suggested by a 12-week pilot study in which the initiation of carvedilol titrated to 50 mg twice daily was associated with a decrease in the frequency of intradialytic hypertensive episodes from 77 to 28 percent of hemodialysis sessions.",
"   </p>",
"   <p>",
"    Limited observational evidence suggests that this increase in blood pressure is associated with adverse outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/127\">",
"     127",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/32/31240?source=see_link\">",
"     \"Hemodynamic instability during hemodialysis: Overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite a paucity of data concerning many aspects of the evaluation and treatment of hypertension in hemodialysis patients, certain general recommendations are appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/1\">",
"     1",
"    </a>",
"    ]. All dialysis patients benefit by a comprehensive evaluation of their cardiovascular status, such as the assessment for traditional risk factors associated with adverse outcomes. Appropriate modalities may include ambulatory blood pressure monitoring and cardiac echocardiography.",
"   </p>",
"   <p>",
"    The target goals should generally be realized based upon individual patient characteristics, with the lowest target BP values being consistent with patient well-being and the absence of intradialytic hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/19\">",
"     19",
"    </a>",
"    ]. For some patients on dialysis, the goal BP is a predialysis value of less than",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg and a post-dialysis value of less than",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/66\">",
"     66",
"    </a>",
"    ]. If clinical characteristics permit and ambulatory pressures are measured, a \"normal\" BP, defined as a mean ambulatory BP less than",
"    <span class=\"nowrap\">",
"     135/85",
"    </span>",
"    mmHg during the day and less than",
"    <span class=\"nowrap\">",
"     120/80",
"    </span>",
"    mmHg at night, is also a reasonable goal.",
"   </p>",
"   <p>",
"    To attain this level of control, the following measures may be utilized [",
"    <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other than those drugs required for any underlying cardiac disease, antihypertensive medications should be",
"      <strong>",
"       slowly",
"      </strong>",
"      withdrawn while uncovering the patient's true dry weight. This process should be undertaken over 3 to 6 weeks among younger patients, and up to 12 to 14 weeks for older individuals and those with vascular pathology.",
"     </li>",
"     <li>",
"      If the blood pressure remains elevated despite the attainment of dry weight, antihypertensive medications should be administered. The choice of drug is based upon the benefits and adverse effects previously delineated, but an antihypertensive agent is preferably administered during the evening with a once per day dosing schedule. The",
"      <span class=\"nowrap\">",
"       K/DOQI",
"      </span>",
"      guidelines suggest that ACE inhibitors or angiotensin II receptor blockers are preferred because they may provide greater benefits, such as relatively more LVH regression [",
"      <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients should be adequately dialyzed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=see_link\">",
"       \"Kt/V and the adequacy of hemodialysis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1962?source=see_link\">",
"       \"Adequacy of peritoneal dialysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Large interdialytic weight gains must be discouraged. As delineated in the",
"      <span class=\"nowrap\">",
"       K/DOQI",
"      </span>",
"      guidelines, management of increased fluid accumulation should be accomplished by consultation with dieticians, low sodium intake, increased ultrafiltration,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      increased dialysis treatments [",
"      <a class=\"abstract\" href=\"UTD.htm?19/46/20202/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Low initial doses of subcutaneous erythropoietin should be administered, and the target hematocrit should be slowly obtained. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=see_link\">",
"       \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=see_link\">",
"       \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/1\">",
"      Mailloux LU, Haley WE. Hypertension in the ESRD patient: pathophysiology, therapy, outcomes, and future directions. Am J Kidney Dis 1998; 32:705.",
"     </a>",
"    </li>",
"    <li>",
"     HCFA-1995. 1995 Annual Report. ESRD core indicators project. Opportunities to improve care for adult in-center hemodialysis patients. Baltimore, MD, Health Care Financing Administration, DHHS, January 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/3\">",
"      Rocco MV, Flanigan MJ, Beaver S, et al. Report from the 1995 Core Indicators for Peritoneal Dialysis Study Group. Am J Kidney Dis 1997; 30:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/4\">",
"      Rahman M, Dixit A, Donley V, et al. Factors associated with inadequate blood pressure control in hypertensive hemodialysis patients. Am J Kidney Dis 1999; 33:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/5\">",
"      Agarwal R, Nissenson AR, Batlle D, et al. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med 2003; 115:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/6\">",
"      Zucchelli P, Santoro A, Zuccala A. Genesis and control of hypertension in hemodialysis patients. Semin Nephrol 1988; 8:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/7\">",
"      Rahman M, Fu P, Sehgal AR, Smith MC. Interdialytic weight gain, compliance with dialysis regimen, and age are independent predictors of blood pressure in hemodialysis patients. Am J Kidney Dis 2000; 35:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/8\">",
"      Mitsnefes M, Stablein D. Hypertension in pediatric patients on long-term dialysis: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Am J Kidney Dis 2005; 45:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/9\">",
"      Amar J, Vernier I, Rossignol E, et al. Nocturnal blood pressure and 24-hour pulse pressure are potent indicators of mortality in hemodialysis patients. Kidney Int 2000; 57:2485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/10\">",
"      Mazzuchi N, Carbonell E, Fern&aacute;ndez-Cean J. Importance of blood pressure control in hemodialysis patient survival. Kidney Int 2000; 58:2147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/11\">",
"      London GM, Pannier B, Guerin AP, et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 2001; 12:2759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/12\">",
"      Salem MM. Hypertension in the haemodialysis population: any relationship to 2-years survival? Nephrol Dial Transplant 1999; 14:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/13\">",
"      Port FK, Hulbert-Shearon TE, Wolfe RA, et al. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis 1999; 33:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/14\">",
"      Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, et al. Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: the 58th annual fall conference and scientific sessions. Hypertension 2005; 45:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/15\">",
"      Stidley CA, Hunt WC, Tentori F, et al. Changing relationship of blood pressure with mortality over time among hemodialysis patients. J Am Soc Nephrol 2006; 17:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/16\">",
"      Udayaraj UP, Steenkamp R, Caskey FJ, et al. Blood pressure and mortality risk on peritoneal dialysis. Am J Kidney Dis 2009; 53:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/17\">",
"      Agarwal R. Hypertension and survival in chronic hemodialysis patients--past lessons and future opportunities. Kidney Int 2005; 67:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/18\">",
"      Mailloux LU, Levey AS. Hypertension in patients with chronic renal disease. Am J Kidney Dis 1998; 32:S120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/19\">",
"      Locatelli F, Covic A, Chazot C, et al. Hypertension and cardiovascular risk assessment in dialysis patients. Nephrol Dial Transplant 2004; 19:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/20\">",
"      Takeda A, Toda T, Fujii T, et al. Discordance of influence of hypertension on mortality and cardiovascular risk in hemodialysis patients. Am J Kidney Dis 2005; 45:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/21\">",
"      Dorhout Mees EJ. Hypertension in haemodialysis patients: who cares? Nephrol Dial Transplant 1999; 14:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/22\">",
"      Salem M. Hypertension in the hemodialysis population? High time for answers. Am J Kidney Dis 1999; 33:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/23\">",
"      Klassen PS, Lowrie EG, Reddan DN, et al. Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA 2002; 287:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/24\">",
"      Tozawa M, Iseki K, Iseki C, Takishita S. Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis. Kidney Int 2002; 61:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/25\">",
"      Baumgart P, Walger P, Gemen S, et al. Blood pressure elevation during the night in chronic renal failure, hemodialysis and after renal transplantation. Nephron 1991; 57:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/26\">",
"      Rodby RA, Vonesh EF, Korbet SM. Blood pressures in hemodialysis and peritoneal dialysis using ambulatory blood pressure monitoring. Am J Kidney Dis 1994; 23:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/27\">",
"      Liu M, Takahashi H, Morita Y, et al. Non-dipping is a potent predictor of cardiovascular mortality and is associated with autonomic dysfunction in haemodialysis patients. Nephrol Dial Transplant 2003; 18:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/28\">",
"      Salem MM. Hypertension in the hemodialysis population: a survey of 649 patients. Am J Kidney Dis 1995; 26:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/29\">",
"      Gross ML, Ritz E. Hypertrophy and fibrosis in the cardiomyopathy of uremia--beyond coronary heart disease. Semin Dial 2008; 21:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/30\">",
"      Kawaguchi Y, Hasegawa T, Nakayama M, et al. Issues affecting the longevity of the continuous peritoneal dialysis therapy. Kidney Int Suppl 1997; 62:S105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/31\">",
"      Tzamaloukas AH, Saddler MC, Murata GH, et al. Symptomatic fluid retention in patients on continuous peritoneal dialysis. J Am Soc Nephrol 1995; 6:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/32\">",
"      Lameire N. Cardiovascular risk factors and blood pressure control in continuous ambulatory peritoneal dialysis. Perit Dial Int 1993; 13 Suppl 2:S394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/33\">",
"      Faller B, Lameire N. Evolution of clinical parameters and peritoneal function in a cohort of CAPD patients followed over 7 years. Nephrol Dial Transplant 1994; 9:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/34\">",
"      Lameire N, Van Biesen W. The impact of residual renal function on the adequacy of peritoneal dialysis. Perit Dial Int 1997; 17 Suppl 2:S102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/35\">",
"      Lameire N, Vanholder RC, Van Loo A, et al. Cardiovascular diseases in peritoneal dialysis patients: the size of the problem. Kidney Int Suppl 1996; 56:S28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/36\">",
"      Thein H, Haloob I, Marshall MR. Associations of a facility level decrease in dialysate sodium concentration with blood pressure and interdialytic weight gain. Nephrol Dial Transplant 2007; 22:2630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/37\">",
"      Raine AE, Bedford L, Simpson AW, et al. Hyperparathyroidism, platelet intracellular free calcium and hypertension in chronic renal failure. Kidney Int 1993; 43:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/38\">",
"      Goldsmith DJ, Covic AA, Venning MC, Ackrill P. Blood pressure reduction after parathyroidectomy for secondary hyperparathyroidism: further evidence implicating calcium homeostasis in blood pressure regulation. Am J Kidney Dis 1996; 27:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/39\">",
"      Argil&eacute;s A, Lorho R, Servel MF, et al. Seasonal modifications in blood pressure are mainly related to interdialytic body weight gain in dialysis patients. Kidney Int 2004; 65:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/40\">",
"      Vertes V, Cangiano JL, Berman LB, Gould A. Hypertension in end-stage renal disease. N Engl J Med 1969; 280:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/41\">",
"      Charra B, Calemard E, Ruffet M, et al. Survival as an index of adequacy of dialysis. Kidney Int 1992; 41:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/42\">",
"      Ozkahya M, T&ouml;z H, Unsal A, et al. Treatment of hypertension in dialysis patients by ultrafiltration: role of cardiac dilatation and time factor. Am J Kidney Dis 1999; 34:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/43\">",
"      G&uuml;nal AI, Duman S, Ozkahya M, et al. Strict volume control normalizes hypertension in peritoneal dialysis patients. Am J Kidney Dis 2001; 37:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/44\">",
"      Hoenich NA, Levin NW. Can technology solve the clinical problem of 'dry weight'? Nephrol Dial Transplant 2003; 18:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/45\">",
"      Aci G, Ozkahya M, Duman S, et al. Volume control associated with better cardiac function in long-term peritoneal dialysis patients. Perit Dial Int 2006; 26:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/46\">",
"      Converse RL Jr, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327:1912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/47\">",
"      Shichiri M, Hirata Y, Ando K, et al. Plasma endothelin levels in hypertension and chronic renal failure. Hypertension 1990; 15:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/48\">",
"      Koyama H, Tabata T, Nishzawa Y, et al. Plasma endothelin levels in patients with uraemia. Lancet 1989; 1:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/49\">",
"      Suzuki N, Matsumoto H, Miyauchi T, et al. Endothelin-3 concentrations in human plasma: the increased concentrations in patients undergoing haemodialysis. Biochem Biophys Res Commun 1990; 169:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/50\">",
"      Vallance P, Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/51\">",
"      Coomer RW, Schulman G, Breyer JA, Shyr Y. Ambulatory blood pressure monitoring in dialysis patients and estimation of mean interdialytic blood pressure. Am J Kidney Dis 1997; 29:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/52\">",
"      Luik AJ, Kooman JP, Leunissen KM. Hypertension in haemodialysis patients: is it only hypervolaemia? Nephrol Dial Transplant 1997; 12:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/53\">",
"      Kooman JP, Gladziwa U, B&ouml;cker G, et al. Blood pressure during the interdialytic period in haemodialysis patients: estimation of representative blood pressure values. Nephrol Dial Transplant 1992; 7:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/54\">",
"      Cheigh, JS. The role of ambulatory blood pressure monitoring in patients with end-stage renal disease. Semin Dial 1998; 11:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/55\">",
"      Cannella G, Paoletti E, Ravera G, et al. Inadequate diagnosis and therapy of arterial hypertension as causes of left ventricular hypertrophy in uremic dialysis patients. Kidney Int 2000; 58:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/56\">",
"      Sankaranarayanan N, Santos SF, Peixoto AJ. Blood pressure measurement in dialysis patients. Adv Chronic Kidney Dis 2004; 11:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/57\">",
"      Thompson AM, Pickering TG. The role of ambulatory blood pressure monitoring in chronic and end-stage renal disease. Kidney Int 2006; 70:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/58\">",
"      Peixoto AJ, Santos SF, Mendes RB, et al. Reproducibility of ambulatory blood pressure monitoring in hemodialysis patients. Am J Kidney Dis 2000; 36:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/59\">",
"      Tripepi G, Fagugli RM, Dattolo P, et al. Prognostic value of 24-hour ambulatory blood pressure monitoring and of night/day ratio in nondiabetic, cardiovascular events-free hemodialysis patients. Kidney Int 2005; 68:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/60\">",
"      Alborzi P, Patel N, Agarwal R. Home blood pressures are of greater prognostic value than hemodialysis unit recordings. Clin J Am Soc Nephrol 2007; 2:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/61\">",
"      Moriya H, Oka M, Maesato K, et al. Weekly averaged blood pressure is more important than a single-point blood pressure measurement in the risk stratification of dialysis patients. Clin J Am Soc Nephrol 2008; 3:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/62\">",
"      Chazot C, Charra B, Laurent G, et al. Interdialysis blood pressure control by long haemodialysis sessions. Nephrol Dial Transplant 1995; 10:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/63\">",
"      Agarwal R, Andersen MJ, Bishu K, Saha C. Home blood pressure monitoring improves the diagnosis of hypertension in hemodialysis patients. Kidney Int 2006; 69:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/64\">",
"      London GM, Marchais SJ, Guerin AP, et al. Salt and water retention and calcium blockade in uremia. Circulation 1990; 82:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/65\">",
"      Mailloux LU. Hypertension in the dialysis patient. Am J Kidney Dis 1999; 34:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/66\">",
"      K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. Am J Kidney Dis 2005; 45(Suppl 3):S49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/67\">",
"      Foley RN, Parfrey PS, Harnett JD, et al. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 1996; 49:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/68\">",
"      Hemodialysis Clinical Practice Guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol 2006; 17(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/69\">",
"      Sch&ouml;mig M, Eisenhardt A, Ritz E. Controversy on optimal blood pressure on haemodialysis: normotensive blood pressure values are essential for survival. Nephrol Dial Transplant 2001; 16:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/70\">",
"      Zager PG, Nikolic J, Brown RH, et al. \"U\" curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int 1998; 54:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/71\">",
"      Li Z, Lacson E Jr, Lowrie EG, et al. The epidemiology of systolic blood pressure and death risk in hemodialysis patients. Am J Kidney Dis 2006; 48:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/72\">",
"      Tentori F, Hunt WC, Rohrscheib M, et al. Which targets in clinical practice guidelines are associated with improved survival in a large dialysis organization? J Am Soc Nephrol 2007; 18:2377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/73\">",
"      Robinson BM, Tong L, Zhang J, et al. Blood pressure levels and mortality risk among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2012; 82:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/74\">",
"      Goldwasser P, Avram MM, Collier JT, et al. Correlates of vascular access occlusion in hemodialysis. Am J Kidney Dis 1994; 24:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/75\">",
"      Culp K, Flanigan M, Taylor L, Rothstein M. Vascular access thrombosis in new hemodialysis patients. Am J Kidney Dis 1995; 26:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/76\">",
"      Chang TI, Paik J, Greene T, et al. Intradialytic hypotension and vascular access thrombosis. J Am Soc Nephrol 2011; 22:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/77\">",
"      Abu-Alfa AK, Burkart J, Piraino B, et al. Approach to fluid management in peritoneal dialysis: a practical algorithm. Kidney Int Suppl 2002; :S8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/78\">",
"      Mailloux LU. The overlooked role of salt restriction in dialysis patients. Semin Dial 2000; 13:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/79\">",
"      Ahmad S. Dietary sodium restriction for hypertension in dialysis patients. Semin Dial 2004; 17:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/80\">",
"      Thomson GE, Waterhouse K, McDonald HP Jr, Friedman EA. Hemodialysis for chronic renal failure. Clinical observations. Arch Intern Med 1967; 120:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/81\">",
"      Raimann J, Liu L, Tyagi S, et al. A fresh look at dry weight. Hemodial Int 2008; 12:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/82\">",
"      Agarwal R, Alborzi P, Satyan S, Light RP. Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial. Hypertension 2009; 53:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/83\">",
"      Agarwal R, Weir MR. Dry-weight: a concept revisited in an effort to avoid medication-directed approaches for blood pressure control in hemodialysis patients. Clin J Am Soc Nephrol 2010; 5:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/84\">",
"      Abraham PA, Opsahl JA, Keshaviah PR, et al. Body fluid spaces and blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. Am J Kidney Dis 1990; 16:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/85\">",
"      Charra B, Laurent G, Chazot C, et al. Clinical assessment of dry weight. Nephrol Dial Transplant 1996; 11 Suppl 2:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/86\">",
"      Joffy S, Rosner MH. Natriuretic peptides in ESRD. Am J Kidney Dis 2005; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/87\">",
"      Jaeger JQ, Mehta RL. Assessment of dry weight in hemodialysis: an overview. J Am Soc Nephrol 1999; 10:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/88\">",
"      Rodriguez HJ, Domenici R, Diroll A, Goykhman I. Assessment of dry weight by monitoring changes in blood volume during hemodialysis using Crit-Line. Kidney Int 2005; 68:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/89\">",
"      Kraemer M, Rode C, Wizemann V. Detection limit of methods to assess fluid status changes in dialysis patients. Kidney Int 2006; 69:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/90\">",
"      Katzarski KS, Nisell J, Randmaa I, et al. A critical evaluation of ultrasound measurement of inferior vena cava diameter in assessing dry weight in normotensive and hypertensive hemodialysis patients. Am J Kidney Dis 1997; 30:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/91\">",
"      Luik AJ, van Kuijk WH, Spek J, et al. Effects of hypervolemia on interdialytic hemodynamics and blood pressure control in hemodialysis patients. Am J Kidney Dis 1997; 30:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/92\">",
"      Fishbane S, Natke E, Maesaka JK. Role of volume overload in dialysis-refractory hypertension. Am J Kidney Dis 1996; 28:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/93\">",
"      Lins RL, Elseviers M, Rogiers P, et al. Importance of volume factors in dialysis related hypertension. Clin Nephrol 1997; 48:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/94\">",
"      Santos SF, Peixoto AJ. Revisiting the dialysate sodium prescription as a tool for better blood pressure and interdialytic weight gain management in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/95\">",
"      Charra B, Bergstr&ouml;m J, Scribner BH. Blood pressure control in dialysis patients: importance of the lag phenomenon. Am J Kidney Dis 1998; 32:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/96\">",
"      Freis ED, Reda DJ, Materson BJ. Volume (weight) loss and blood pressure response following thiazide diuretics. Hypertension 1988; 12:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/97\">",
"      McGregor DO, Buttimore AL, Nicholls MG, Lynn KL. Ambulatory blood pressure monitoring in patients receiving long, slow home haemodialysis. Nephrol Dial Transplant 1999; 14:2676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/98\">",
"      Covic A, Goldsmith DJ, Venning MC, Ackrill P. Long-hours home haemodialysis--the best renal replacement therapy method? QJM 1999; 92:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/99\">",
"      Katzarski KS, Charra B, Luik AJ, et al. Fluid state and blood pressure control in patients treated with long and short haemodialysis. Nephrol Dial Transplant 1999; 14:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/100\">",
"      Agarwal R. Systolic hypertension in hemodialysis patients. Semin Dial 2003; 16:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/101\">",
"      Tattersall, J, Martin-Malo, A, Pedrini, L, et al. European best practice guidelines on haemodialysis. Nephrol Dial Transplant 2007; 22(Suppl 2):ii1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/102\">",
"      Heerspink HJ, Ninomiya T, Zoungas S, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 2009; 373:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/103\">",
"      Tomson CR. Blood pressure and outcome in patients on dialysis. Lancet 2009; 373:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/104\">",
"      Venkatesan J, Henrich WL. Anemia, hypertension, and myocardial dysfunction in end-stage renal disease. Semin Nephrol 1997; 17:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/105\">",
"      Tepel M, Hopfenmueller W, Scholze A, et al. Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrol Dial Transplant 2008; 23:3605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/106\">",
"      K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations 2006 Updates Hemodialysis adequacy Peritoneal Dialysis Adequacy Vascular Access. Am J Kidney Dis 2006; 48(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/107\">",
"      Cannella G, Paoletti E, Delfino R, et al. Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis 1997; 30:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/108\">",
"      Tai DJ, Lim TW, James MT, et al. Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis: a meta-analysis. Clin J Am Soc Nephrol 2010; 5:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/109\">",
"      Zannad F, Kessler M, Lehert P, et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006; 70:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/110\">",
"      Efrati S, Zaidenstein R, Dishy V, et al. ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 2002; 40:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/111\">",
"      Bajaj RR, Wald R, Hackam DG, et al. Use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and cardiovascular outcomes in chronic dialysis patients: a population-based cohort study. Arch Intern Med 2012; 172:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/112\">",
"      Dhondt AW, Vanholder RC, Ringoir SM. Angiotensin-converting enzyme inhibitors and higher erythropoietin requirement in chronic haemodialysis patients. Nephrol Dial Transplant 1995; 10:2107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/113\">",
"      Le Meur Y, Lorgeot V, Comte L, et al. Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements. Am J Kidney Dis 2001; 38:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/114\">",
"      H&ouml;rl MP, H&ouml;rl WH. Drug therapy for hypertension in hemodialysis patients. Semin Dial 2004; 17:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/115\">",
"      Suzuki H, Kanno Y, Sugahara S, et al. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis 2008; 52:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/116\">",
"      John B, Anijeet HK, Ahmad R. Anaphylactic reaction during haemodialysis on AN69 membrane in a patient receiving angiotensin II receptor antagonist. Nephrol Dial Transplant 2001; 16:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/117\">",
"      Krieter DH, Canaud B. Anaphylactic reaction during haemodialysis on AN69 membrane in a patient receiving angiotensin II receptor antagonist. Nephrol Dial Transplant 2002; 17:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/118\">",
"      Ross EA, Pittman TB, Koo LC. Strategy for the treatment of noncompliant hypertensive hemodialysis patients. Int J Artif Organs 2002; 25:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/119\">",
"      Flanigan MJ, Khairullah QT, Lim VS. Dialysate sodium delivery can alter chronic blood pressure management. Am J Kidney Dis 1997; 29:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/120\">",
"      Krautzig S, Janssen U, Koch KM, et al. Dietary salt restriction and reduction of dialysate sodium to control hypertension in maintenance haemodialysis patients. Nephrol Dial Transplant 1998; 13:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/121\">",
"      Saldanha LF, Weiler EW, Gonick HC. Effect of continuous ambulatory peritoneal dialysis on blood pressure control. Am J Kidney Dis 1993; 21:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/122\">",
"      Young, M, Nolph, K, Dutton, S, et al. Antihypertensive drug requirements in continuous ambulatory peritoneal dialysis. Perit Dial Bull 1984; 4:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/123\">",
"      Cannata, JB, Isles, CG, Briggs, JD, Junor, BJ. Comparison of blood pressure control during hemodialysis and CAPD. Dial Transplant 1986; 12:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/124\">",
"      Zazgornik J, Biesenbach G, Janko O, et al. Bilateral nephrectomy: the best, but often overlooked, treatment for refractory hypertension in hemodialysis patients. Am J Hypertens 1998; 11:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/125\">",
"      Chou KJ, Lee PT, Chen CL, et al. Physiological changes during hemodialysis in patients with intradialysis hypertension. Kidney Int 2006; 69:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/126\">",
"      Inrig JK, Van Buren P, Kim C, et al. Intradialytic hypertension and its association with endothelial cell dysfunction. Clin J Am Soc Nephrol 2011; 6:2016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/46/20202/abstract/127\">",
"      Inrig JK, Patel UD, Toto RD, Szczech LA. Association of blood pressure increases during hemodialysis with 2-year mortality in incident hemodialysis patients: a secondary analysis of the Dialysis Morbidity and Mortality Wave 2 Study. Am J Kidney Dis 2009; 54:881.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1848 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-A1F0AAE071-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_46_20202=[""].join("\n");
var outline_f19_46_20202=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Volume overload",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Increased sympathetic activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Altered endothelial cell function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Erythropoietin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      METHOD OF BLOOD PRESSURE MEASUREMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      OPTIMAL BLOOD PRESSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Control of volume status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Prolonged and/or more frequent hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Antihypertensive medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - ACE inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - ARBs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Central sympathetic agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Reduced dialysate sodium concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Refractory hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      HYPERTENSION DURING HEMODIALYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1962?source=related_link\">",
"      Adequacy of peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13175?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33433?source=related_link\">",
"      Chronic kidney disease associated with atherosclerotic renovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17959?source=related_link\">",
"      Clinical implications and treatment of left ventricular hypertrophy in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10857?source=related_link\">",
"      Erythrocytosis following renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/32/31240?source=related_link\">",
"      Hemodynamic instability during hemodialysis: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/15/8436?source=related_link\">",
"      Hypertension following erythropoietin in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/55/30582?source=related_link\">",
"      Hypertension in autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/12/26823?source=related_link\">",
"      Increased pulse pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=related_link\">",
"      Kt/V and the adequacy of hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/2/18473?source=related_link\">",
"      Major side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26584?source=related_link\">",
"      Myocardial dysfunction in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42674?source=related_link\">",
"      NSAIDs and acetaminophen: Effects on blood pressure and hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=related_link\">",
"      Patient survival and maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23337?source=related_link\">",
"      Problems with solute clearance and ultrafiltration in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/12/4295?source=related_link\">",
"      Reactions to the hemodialysis membrane",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25224?source=related_link\">",
"      Renin-angiotensin system inhibition in the treatment of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18137?source=related_link\">",
"      Short daily hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/16/264?source=related_link\">",
"      Technical aspects of nocturnal hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_46_20203="Fluoride content bottled water";
var content_f19_46_20203=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Fluoride content of some bottled water",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type of water",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of specimens",
"       </td>",
"       <td class=\"subtitle1\">",
"        Range of fluoride content (mg/L*)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Artesian",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td>",
"        &lt;0.10 to 0.25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Distilled",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"       <td>",
"        &lt;0.10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drinking",
"       </td>",
"       <td class=\"centered\">",
"        8",
"       </td>",
"       <td>",
"        &lt;0.10 to 0.94 (4 samples had &lt;0.10 mg/L and 4 had &ge;0.65 mg/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Purified",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td>",
"        &lt;0.10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spring",
"       </td>",
"       <td class=\"centered\">",
"        36",
"       </td>",
"       <td>",
"        &lt;0.10 to 0.73 (34 of 36 specimens had &lt;0.3 mg/L; only 2 had &gt;0.3 mg/L)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * 1 mg/L = 1 part per million.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Lalumandier JA, Ayers LW. Fluoride and bacterial content of bottled water vs tap water. Arch Fam Med 2000; 9:246.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_46_20203=[""].join("\n");
var outline_f19_46_20203=null;
var title_f19_46_20204="Classes of ERCP complications";
var content_f19_46_20204=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of site, timing, and severity of complications related to endoscopic retrograde cholangiopancreatography (ERCP)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Site",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Focal",
"       </td>",
"       <td>",
"        Occurring at the point of endoscopic contact",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonspecific",
"       </td>",
"       <td>",
"        Occurring in organs not traversed or treated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Timing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immediate",
"       </td>",
"       <td>",
"        Occurring during ERCP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Early",
"       </td>",
"       <td>",
"        Evident within the recovery period",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Delayed",
"       </td>",
"       <td>",
"        Focal (occurring within 30 days)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonspecific (first symptom presenting within 3 days)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Late",
"       </td>",
"       <td>",
"        Evident after months or years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Criteria for severity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Length of stay",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mild",
"       </td>",
"       <td>",
"        &le;3 nights",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Moderate",
"       </td>",
"       <td>",
"        4 to 10 nights",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Severe",
"       </td>",
"       <td>",
"        &gt;10 nights, ICU admission, or surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fatal",
"       </td>",
"       <td>",
"        Death attributable to the procedure within 30 days (or longer if under continued in-patient treatment for the complication)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Other indices of severity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Need for blood transfusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Additional interventions (endoscopic or radiologic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Total length of stay",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Permanent residual disability",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Cotton PB, Gastrointest Endosc 1994; 40:514 and Aliperti G, et al, Gastrointest Endosc Clin N Am 1996; 6:379.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_46_20204=[""].join("\n");
var outline_f19_46_20204=null;
var title_f19_46_20205="ACEI vs hydralazine in HF";
var content_f19_46_20205=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64938&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64938&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    ACE inhibitor more effective than hydralazine and nitrates in HF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 249px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Enalapril is associated with diminished mortality when compared to the combination of hydralazine-isosorbide dinitrate (Hydral-IDN) in patients with moderate NYHA class II or III heart failure. (p = 0.016 at two years [18 versus 25 percent] and p = 0.08 at five years [48 versus 54 percent].)",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Cohn JN, Johnson G, Ziesche S, et al. N Engl J Med 1991; 325:303.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_46_20205=[""].join("\n");
var outline_f19_46_20205=null;
var title_f19_46_20206="Time course of ODS";
var content_f19_46_20206=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F76131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F76131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Delayed appearance of osmotic demyelination and relowering of the serum sodium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 366px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Neurologic symptoms of ODS typically occur two to six days after correction of the hyponatremia. In this patient, severe hyponatremia was corrected too quickly (23 meq/L in 48 hours), and coma developed two days later. The serum sodium was quickly relowered, and then slowly corrected. Neurologic symptoms improved, which may have been due to relowering of the serum sodium, or may have represented spontaneous resolution.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Oya S, Tsutsumi K, Ueki K, Kirino T. Reinduction of hyponatremia to treat central pontine myelinolysis. Neurology 2001; 57:1931. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_46_20206=[""].join("\n");
var outline_f19_46_20206=null;
var title_f19_46_20207="Pathway of the biosynthesis of DHA";
var content_f19_46_20207=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F87057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F87057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 623px\">",
"   <div class=\"ttl\">",
"    Pathway of the biosynthesis of docosahexaenoic acid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 603px; height: 367px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The pathway of the biosynthesis of docosahexaenoic acid (DHA) and inhibitory effects that the preterm diet and steroids could have on the ability to internally synthesize adequate DHA.",
"    <div class=\"footnotes\">",
"     DGLA: di-homo &gamma;-linolenic acid; DPA: docosapentaenoic acid; EPA: eicosapentaenoic acid; ETA: eicosatetraenoic acid; GLA: &gamma;-linolenic acid; PGs: prostaglandins; SA: stearidonic acid; AA: arachidonic acid; DHA: docosahexaenoic acid; LA: linoleic acid; ALA: alpha-linoleic acid.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Valentine CJ. Maternal dietary DHA supplementation to improve inflammatory outcomes in the preterm infant. Advances in Nutrition: An International Review Journal (2012; 3:370-6). Copyright &copy; 2012 American Society for Nutrition.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_46_20207=[""].join("\n");
var outline_f19_46_20207=null;
